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Introduction and Outline of the Thesis
Chronic Obstructive Disease (COPD) is characterized by progressive and irreversible 
airway obstruction. It is associated with chronic infl ammation in the lungs, which 
is thought to be initiated by the inhalation of noxious particles and gases such as 
cigarette smoke.1;2 The chronic infl ammatory response is characterized by cellular 
infi ltrates, as well as production of infl ammatory mediators, proteinases, and reactive 
nitrogen and oxygen species. The intensity and characteristics of the infl ammatory 
process vary as the disease progresses.3-5
There is increasing evidence of systemic (i.e. extrapulmonary) effects in patients 
with COPD (reviewed in 6). Similarly to the observation in the airways, increased 
amounts of activated neutrophils have been observed in the circulation of COPD 
patients in a clinical stable situation.7 Also, increased activation of circulating 
lymphocytes, as indicated by enhanced expression of cytochrome oxidase, has been 
demonstrated.8 Several studies investigating infl ammatory mediators in COPD, 
reported enhanced concentrations of acute-phase proteins, such as C-reactive protein 
(CRP), lipopolysaccharide (LPS) binding protein (LBP) and fi brinogen, along with 
increases in plasma levels of (pro)infl ammatory cytokines like IL-6, IL-8 and TNF-α 
and its receptors.9-13 Besides infl ammation, evidence for systemic oxidative stress in 
COPD was obtained. Increased production of free radicals or insuffi cient antioxidant 
capacity leads to a disbalance between oxidants and antioxidants. An excessive 
amount of free radicals may be harmful to tissues by inducing functional or structural 
alterations.14 Several investigations have shown that markers of oxidative stress (e.g. 
antioxidant capacity, lipid peroxidation, and peroxidation of arachidonic acid) are 
increased in patients with COPD and even more pronounced during exacerbations.15-18
In addition to systemic infl ammation and oxidative stress, muscle wasting and 
muscle dysfunction are noted in some COPD patients.19-21 These muscular changes 
are inversely related to physical performance 22;23, susceptibility to exacerbations 
and outcome prognosis.24;25 Causative factors for these muscle disturbances might be 
multi-factorial, but infl ammation and oxidative stress are increasingly recognized to 
be involved in its pathogenesis.6
Besides airfl ow limitation, muscle wasting and muscle dysfunction have been 
shown to play a role in dyspnea and exercise limitation, two common complaints in 
COPD.26 The interactions between exercise stress and the immune system provide 
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a unique opportunity to link basic and clinical physiology and to evaluate the role 
of underlying stress and immunophysiologic mechanisms. It is known that exercise, 
if suffi ciently intense, leads to a highly stereotyped immune response in healthy 
subjects, mediated by an interplay of infl ammatory cells, hormones, cytokines, 
neural and hematological factors 27, that can also affect distant organs.28 Since COPD 
patients already show signs of systemic infl ammation, elevated levels of circulating 
catecholamines, marked sympathetic activation 29;30 and muscle wasting 31 at rest, it 
may be expected that physical activity will further increase these mediators. Indeed, 
recently it was shown that moderate intensity exercise in COPD abnormally increased 
plasma tumor necrosis factor-alpha (TNF-α) levels.32 Moreover, strenuous exercise 
induces systemic 15;33;34 and muscle 35 oxidative stress in COPD patients. 
It has been postulated that frequent exposure to these effects during daily living 
might negatively affect tissues (for example skeletal muscles) and thereby play a 
role in the ongoing systemic infl ammation and oxidative stress and progression of 
COPD. This thesis is focused on the exercise-induced immune response in patients 
with COPD.
In chapter 3 the systemic leukocytosis and the stress response to exhaustive exercise 
in patients with COPD were characterized. The response to a maximal incremental 
bicycle test was compared between COPD patients and healthy subjects. Circulating 
leukocytes and their subsets were counted before, during and after the exercise 
to compare the leukocytosis to exercise between both groups. Plasma levels of 
catecholamines and cortisol were measured to evaluate the stress response. Creatine 
kinase and myoglobin were determined in the blood to see if muscle damage could 
be detected systemically.
The immune response and its possible relation with muscle wasting and dysfunction 
in COPD was investigated in chapter 4. Pulmonary function, body composition, 
muscle strength, and chronic systemic infl ammation and oxidative stress were 
studied within healthy subjects, patients with COPD, and muscle-wasted patients 
with COPD. Also, the exercise-induced systemic effects were evaluated after a 
maximal and a submaximal cycle test. Leukocyte counts, and infl ammatory mediators 
(TNF-α, IL-1RA, IL-6, IL-8) were used for characterization of the infl ammatory 
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process. Free radical production by neutrophils, plasma antioxidant capacity, lipid 
peroxidation, protein oxidation, and glutathione oxidation were used as markers for 
oxidative stress.
In chapter 5, we investigated whether a probably less intense and more regularly 
performed physical activity than high intensity cycling, namely 6 minutes of 
walking, affected the systemic immunology in patients with COPD. The physiologic 
and systemic immunologic responses to a 6-minute walking test (6MWT) were 
determined in muscle-wasted COPD patients and compared with the responses to 
maximal cardiopulmonary exercises testing (CPET). A mobile oxycon was used for 
characterization of the exercise-physiology during the 6MWT. The exercise-induced 
immune response was followed using the parameters described in chapter 4.
Several strategies may be able to modulate the infl ammatory response and the 
oxidant/antioxidant balance related to exercise. We have studied the effect of short 
term oxygen breathing (nasal, 4L·min-1) on both basal systemic infl ammation and 
oxidative stress (1h treatment with oxygen or compressed air) and exercise-induced 
systemic effects in muscle-wasted COPD patients (chapter 6). Before and after 
breathing oxygen for 1h (randomized, placebo controlled) blood samples were taken 
to analyse markers for infl ammation and oxidative stress. Subsequently, before and 
after cycling (40W, constant work rate) with oxygen or compressed air, the immune 
response was evaluated.
The most remarkable fi ndings of this thesis are integrated in the summary and 
conclusions (chapter 7). Revealing the consequences and mechanisms of systemic 
effects of COPD is considered to have high priority in future research to fi nd new 
targets for therapies and optimize the treatment of these patients.
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Abstract
Chronic obstructive pulmonary disease (COPD) is no longer seen as a pulmonary 
disease, but is increasingly associated with systemic effects with important clinical 
relevance. Systemic immunological changes in COPD patients are characterized 
by an increased number of circulating infl ammatory cells, functional changes of 
the infl ammatory cells, elevated plasma levels of cytokines, and oxidative stress. 
Physical exercise induces an abnormal systemic infl ammatory and oxidative response 
in COPD patients, which is seen in both the circulation and the peripheral muscles. 
Although mechanisms and consequences of these effects are not yet fully understood, 
they could be harmful in COPD patients by inducing damage or functional changes 
in, for example, skeletal muscles. Whether these changes of the immune system 
can also affect the susceptibility to infections in these patients is unknown. The 
concept of COPD as a systemic rather than only a pulmonary disease also opens new 
perspectives on the development of new therapeutic interventions. The effects of new 
anti-oxidative and anti-infl ammatory agents are investigated. A better understanding 
of the complexity of the systemic effects will aid to the development of new therapies 
and management strategies for patients with COPD.  
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Introduction
“Chronic Obstructive Pulmonary Disease (COPD) is a disease state characterized 
by airfl ow limitation that is not fully reversible. The airfl ow limitation is usually 
progressive and associated with an abnormal infl ammatory response of the lungs to 
noxious particles or gases”.1 This defi nition of COPD focuses exclusively on the lungs. 
Therefore, it is not surprising that in the diagnosis, staging, prognosis, and therapy of 
the disease mainly pulmonary variables are considered.1 Changes are introduced now, 
since recent studies have provided evidence that COPD is often associated with extra-
pulmonary abnormalities (Table 1).2 Systemic features of COPD are recognized as 
an important clinical feature of the disease and contribute signifi cantly to decreased 
exercise capacity, decreased health status and increased mortality.2;3 For example, a 
multidimensional grading system was introduced recently to predict the risk of death 
among patients with COPD.4 Besides the forced expiratory volume in 1 second and 
the dyspnea score, this index also contains the 6-minute walking test, and the body 
mass index. For the fi rst time, both pulmonary and systemic effects of COPD are 
integrated to stage the severity and estimate prognosis of the disease. Integration of 
both pulmonary and systemic effects and its consequences may contribute to a better 
understanding and management of the disease.
Exercise limitation, a common complaint in COPD patients 5 and a signifi cant 
contributor to the poor quality of life 6;7, has traditionally been explained by the 
increased work of breathing and dynamic hyperinfl ation that results from the airfl ow 
limitations in COPD patients.8;9 However, physical activity does not only affect the 
cardiovascular and respiratory system, but also has effects on the immune system 
and the skeletalmuscular system.10;11 The identifi cation of systemic effects, like 
infl ammation, oxidative stress and skeletal muscle wasting in COPD patients, has 
not only caused a shift in the view of the pathophysiology of COPD, but has also 
drawn attention to the role of exercise and rehabilitation in these patients.12 Until 
now, multiple studies have characterized the exercise-induced immune response in 
healthy subjects. However, regarding the immune response to exercise in COPD 
patients, a lot of information is still missing. 
In this article, current knowledge regarding basal and exercise-induced systemic 
immunology, including infl ammation and oxidative stress in patients with COPD is 
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reviewed and potential mechanisms and clinical consequences are discussed. Based 
on these data, targets for investigation of better clinical management of these patients 
are suggested.
Systemic immunological changes in COPD Patients
At rest
Intrapulmonary infl ammation and oxidative stress play a key role in the pathogenesis 
of COPD. Increased numbers of neutrophils, macrophages and T-lymphocytes as 
well as elevated concentrations of pro-infl ammatory cytokines and oxidative stress 
are characteristic features within COPD.13 However, recent studies have shown that 
infl ammation and oxidative stress are also present systemically (Table 2). 
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For example, increased numbers of circulating leukocytes were found in stable patients 
with COPD.14-16 Furthermore, neutrophils harvested from the circulation of COPD 
patients showed enhanced chemotaxis and extracellular proteolysis.17 In another 
study, these cells produced more reactive oxygen species (the so called oxidative 
burst) compared with those from healthy subjects.18 Additionally, the expression of 
several surface adhesion molecules on neutrophils (for example CD11b), that play 
a role in the attraction and migration of cells, was higher in stable COPD patients 
than in healthy controls. Other abnormalities described in circulating neutrophils in 
COPD patients include the downregulation of a G-protein subunit (stimulatory Gα) 
that is indirectly involved in the expression of adhesion molecules and the oxidative 
burst.15
Little is known about the function of circulating lymphocytes in COPD. Sauleda 
et al.19 showed that the activity of cytochrome oxidase, the terminal enzyme in the 
mitochondrial electron transport chain, was increased in circulating lymphocytes 
from stable COPD patients compared with healthy non-smoking controls. This 
abnormality was also detected in other chronic infl ammatory diseases 20, suggesting 
that it may be a non-specifi c marker of lymphocyte activation. Further, a higher 
percentage of CD8+ lymphocytes was found in COPD patients 21 compared with 
healthy subjects. Additionally, a lower CD4+/CD8+ ratio was associated with a 
decreased pulmonary function. The implication of these fi ndings remains unclear. 
Because the CD4+/CD8+ ratio is genetically controlled in humans, it could be 
hypothesized that a smoker with a low CD4+/CD8+ ratio may be more susceptible 
for the development of COPD.
Next to infl ammatory cells, numerous studies have reported increased levels of 
circulating cytokines and acute phase proteins in the peripheral circulation of patients 
with COPD.22-26 Abnormalities include increased concentrations of tumor necrosis 
factor (TNF)-α, its receptors (TNFR-55 and TNFR-75), interleukin (IL)-6, IL-8, and 
Fas and Fas ligand, as well as elevated levels of the acute-phase proteins C-reactive 
protein and lipopolysaccharide-binding protein. These increases were seen in 
clinically stable patients, but were generally more pronounced during exacerbations 
of the disease. 
Besides infl ammation, oxidative stress also plays an important role in the pathogenesis 
of COPD.13 Increased production of reactive oxygen species (by neutrophils) 
or insuffi cient antioxidant capacity leads to a disbalance between oxidants and 
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antioxidants. An excessive amount of reactive oxygen species may be harmful to 
tissues by inducing functional or structural alterations.27 Different investigations 
have shown that markers of oxidative stress (antioxidant capacity, lipid peroxidation, 
and peroxidation of arachidonic acid) are increased in patients with COPD and even 
more pronounced during exacerbations.12;28;29 Higher levels of oxidative stress found 
in smokers with a normal pulmonary function suggests that tobacco smoke plays a 
role in disturbing the balance between oxidants and antioxidants.
The mechanisms of the above-mentioned systemic immunological changes in COPD 
patients are unclear, but several mechanisms could be operative (for a review, see 
ref. 2). Firstly, tobacco smoke can cause endothelial damage and dysfunction of 
the systemic vessels 30;31, as well as systemic oxidative stress.32 A second potential 
mechanism is that the pulmonary infl ammatory process in the lung in COPD patients 
is the source of the systemic infl ammation. Cytokines and oxidants, produced by the 
infl ammatory cells in the lung, can reach the systemic circulation and/or contribute to 
the activation of infl ammatory cells during transit through the pulmonary circulation. 
A third possibility is that some of the aspects of the systemic immunological 
abnormalities in COPD patients may be a cause rather than a consequence of COPD. 
This possibility is based upon the following observations. Only a percentage of all 
smokers eventually develops COPD 33, suggesting that the participation of other 
factors, for example genetic factors, is also important in the pathogenesis of COPD.34 
The abnormalities seen in the neutrophils of COPD patients could be the expression 
of a genetic predisposition that renders these cells more susceptible to the effects of 
smoking and other pro-infl ammatory agents. A more vigorous response to the same 
degree of stimulation would be the fi rst step in a chain of reactions causing the fi nal 
systemic infl ammation and oxidative stress and their enhanced damaging potential.
After exercise
From literature about exercise and sports it is known that exercise, if suffi ciently 
intense, leads to a highly stereotyped immune response in healthy subjects, mediated 
by an interplay of metabolic, endocrine and immunological factors.35 Dependent on 
type, duration and intensity, exercise induces an increase in plasma concentrations 
of the stress hormones epinephrine, norepinephrine, β-endorphin, growth hormones, 
and cortisol.36 In healthy subjects, arterial plasma concentrations of epinephrine and 
norepinephrine increase almost linearly with the duration of the dynamic exercise 
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and exponentially with the intensity, when expressed relative to the individual’s 
O2-max. In contrast, cortisol concentrations increase only in relation to exercise of long 
duration. The exercise-induced immune response in patients with COPD is poorly 
investigated. Colice et al.37 investigated the hormonal response to maximal exercise 
in COPD patients who became hypoxic during exercise, and reported that the rate of 
increase in epinephrine (but not norepinephrine) with maximal exercise was smaller 
compared with healthy subjects. In contrast, the hormonal response to exercise in 
normoxic COPD patients has been found to be comparable with the response found 
in healthy subjects.16 These fi ndings support the idea that hypoxia may interfere with 
the adrenal medullary response to exercise.
Regarding the interplay of systems involved in the response to exercise seen in 
healthy subjects and the basal immunological abnormalities seen in COPD patients, 
the immunological response to exercise in these patients may be very interesting. 
Despite variation in intensity and duration of the exercise and the fi tness level 
between healthy subjects and COPD patients, several consistent patterns regarding 
the leukocyte subpopulations in blood were recently described.16 The response to 
exercise refl ected an early leukocytosis in all subsets in both groups, followed by 
a second phase during which neutrophils gradually increased and lymphocytes 
concentrations rapidly fell. Although the response patterns of the infl ammatory cells 
were similar in controls and patients, the whole leukocytosis occurred at an elevated 
level in the patients because of their low-grade systemic infl ammation at rest. The 
high numbers of these cells and their function may be important in the onset of further 
infl ammatory and oxidative cascades. For example, an increased phagocytosis and 
decreased oxidative burst of neutrophils in healthy subjects are functional changes 
that are suggested to be protective against the release of damaging mediators that 
induce intense infl ammatory reactions.38 However, very recent data show an increase 
in the oxidative burst of neutrophils of COPD patients in response to high-intensity 
exercise.39;40 Although only hypothetical, this response might induce substantial 
damage to tissues by the release of free radicals. Additionally, the response to exercise 
involves an increased production and release of circulating infl ammatory and pro-
infl ammatory cytokines. The circulation of high concentrations of TNF-α, IL-1β, IL-6 
and IL-1 receptor antagonist after intensive exercise in athletes is even compared 
with a septic or traumatic response.41 Although a lot is known about the low-grade 
increases in basal cytokine concentrations in COPD patients, only two studies have 
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investigated the effect of exercise on these mediators. Firstly, Rabinovich et al.42 
have shown that submaximal exercise (40% Wmax, 11 min) already induces an 
abnormal increase in plasma TNF-α levels in COPD patients. Supplementary, in 
another study 43, levels of IL-6 have been found to increase after both maximal and 
submaximal (50% Wmax, 30 minutes) exercise in especially muscle-wasted COPD 
patients compared with healthy subjects.
Besides the above-mentioned hormonal and infl ammatory response, oxidative stress 
also plays a key role in the systemic response to exercise. In healthy subjects, only 
intense exercise induces glutathione oxidation in blood (reduced glutathioine to 
oxidized glutathione).44;45 However, exercise with a relative low external workload 
already induces glutathione oxidation in COPD patients.46;47  Within this oxidation, 
it has been shown that the endogenous enzyme xanthine-oxidase plays an important 
role in the formation of free radicals.46 In the above-mentioned studies, oxidation of 
glutathione in patients with COPD is accompanied by an increase in lipid peroxidation 
(e.g., malondialdehyde, thiobarbituric acid-reactive substances), a marker for free 
radical-mediated tissue damage. Furthermore, recently, it has been reported that 
exercise induces free radical-induced DNA damage in patients with COPD. 12 Not 
only in the systemic circulation, but also in the peripheral muscles, oxidative stress 
was elevated after exercise in patients with COPD.48;49 Together, these data suggest 
that exercise in patients with COPD induces oxidative stress that is accompanied 
with tissue damage, which may be involved in the ongoing immunological changes 
and progression of the disease.
Consequences of systemic infl ammation and oxidative stress
During daily life, patients with COPD will frequently perform physical activities at a 
relatively high percentage of their maximal exercise capacity. Although not yet proven, 
it seems likely that these activities may infl uence both the number and function of 
the immunocompetent cells and the level of systemic oxidative stress. Consequently, 
these patients may be exposed to repeated bursts of systemic immunological 
responses, which may affect peripheral tissues and organs 50 by inducing damage 
or functional changes in, for example, skeletal muscles. Furthermore, it would be 
relevant to investigate if this exercise-induced immune response also plays a role in 
the decreased defense against infections in patients with COPD.
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Effect on peripheral skeletal muscles
The concept that exercise intolerance in COPD patients is due to dyspnea, in turn 
caused by increased work of breathing secondary to airfl ow limitation 8;9, was for the 
fi rst time challenged by Killian et al.51 They showed that many patients with COPD 
stop exercising because of leg fatigue rather than dyspnea. Since then, skeletal muscle 
dysfunction in COPD is seen as an important systemic effect of COPD and has been 
extensively studied, but its mechanism is still poorly understood. Exercise intolerance 
in COPD patients leads to adoption of a sedentary lifestyle, which in turn causes loss 
of muscle mass, reduction in force generating capacity of the muscles and a decrease 
in resistance to fatigue.52 Consequently,  the exercise capacity further decreases, 
resulting in progressive sedentarism. Briefl y, patients fall into a vicious circle that 
worsens their disease state. Exercise training improves condition, muscle function, 
and muscle mass 53-55, but complete normalization of muscle physiology is often not 
fully achieved after rehabilitation. Therefore, it is likely that also mechanisms other 
than inactivity might play a role in skeletal muscle dysfunction in patients with COPD 
(Table 3). One of the important potential mechanisms is systemic infl ammation. The 
aforementioned low-grade systemic infl ammation in patients with COPD and the 
elevations after exercise may increase levels of infl ammation at the level of local 
organ systems like the liver 56, heart 57;58, or skeletal muscle.42;59 Cytokines can affect 
muscle cells in a number of ways. TNF-α, for example, activates the transcription 
factor nuclear factor-κB and degrades myosin heavy chains through activation of the 
ubiquitin/proteasome complex.60 Dysregulation of this complex has been associated 
with loss of muscle function and muscle mass. Alternatively, TNF-α can activate 
the leukocytes and induce the expression of several genes that encode for TNF-α 
itself and many other pro-infl ammatory cytokines, which would create a closed loop 
and contribute to the persistence and amplifi cation of the infl ammatory cascade.60 
Finally, TNF-α can induce apoptosis of several cell systems 61, and recently it has 
been shown that excessive apoptosis of muscle cells occurs in patients with COPD.62 
Moreover, systemic infl ammation (overexpression of IL-6) may also be the cause 
of suppression of the growth hormone/insulin-like growth factor-1 axis, as is seen 
in chronic diseases 63;64, and is associated with loss of skeletal muscle.65 According 
to Table 3, not only systemic infl ammation, but also increased levels of systemic 
oxidative stress may be a potential mechanism in the pathogenesis of skeletal muscle 
dysfunction in COPD patients. Among other things, oxidative stress causes muscle 
fatigue 66 and supports proteolysis of muscle cells.67;68 Furthermore, oxidative stress 
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contributes to the gradual loss of muscle mass that occurs in the normal process of 
ageing.69;70 Whether this process occurs early or is accelerated in COPD patients with 
muscle wasting has not yet been explored.
Shortly, muscle wasting and dysfunction in patients with COPD are probably caused 
by multiple mechanisms, including systemic infl ammation and oxidative stress. 
Keeping this in mind, the increased systemic effects in response to exercise might 
negatively affect the skeletal muscles of these patients.
Risk of infections
Changes within the immune system may infl uence the defense against infections. 
Epidemiological data on exercise training and the risk of minor illnesses such as 
upper airway infections have shown that the relation between physical activity and 
the risk of infections can be illustrated by the so called (symptom-based) J-curve 71. 
Regarding this curve, regular moderate activity will enhance resistance to infections, 
whereas intense exercise suppresses this resistance in the healthy population. 
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However, symptoms of infections after exercise are never causally related to 
exercise-induced changes of the immune system. Whether the risk of infections in 
patients with COPD resembles this curve is unknown. Firstly, the susceptibility of 
COPD patients to respiratory infections is much higher than in healthy subjects.72;73 
Therefore, the curve would already start at a higher risk of infections. This higher risk 
is accompanied with low-grade basal systemic infl ammation and oxidative stress as 
described before, which is even more intensifi ed during exercise in comparison with 
healthy subjects. Although the function of the immunocompetent cells after exercise 
is not yet investigated, the intensifi ed levels might be characteristic for a further 
elevated risk of infections in patients with COPD. To fi nd out whether the relation 
between physical activity and the risk of infection in patients with COPD can be 
illustrated by a similar J-curve on a higher level or maybe by a linear or logarithmic 
relation (Figure 1), further investigations into the exercise-induced effects on the 
immune system in patients with COPD are needed, as well as causal studies on the 
relation between these effects and the occurrence of infections.
Figure 1. Possible J-curve for patients with COPD.
The relationship between physical activity and infection risk in patients with COPD is unknown. Based 
on studies about the systemic immunology in these patients, the curve will start at a higher risk of 
infections than in healthy subjects. For now, it can only be speculated whether the activity level and 
risk of infection can be illustrated as 1) a J-curve on a higher level, 2) a linear relationship, or 3) a 
logarithmic relation.
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Therapeutic interventions
Pharmacological interventions
Since COPD is recognized as a systemic rather than only a pulmonary disease, the 
development of new therapeutic interventions has found new targets to manage this 
diffi cult disease. The presence of low-grade systemic infl ammation and oxidative 
stress in COPD patients is the scientifi c rationale for the development of anti-
infl ammatory and anti-oxidative therapies. Antioxidants play an important role in 
the protection of tissues against free radical-mediated damage. Supplementation of 
effective antioxidants may repair the imbalance between oxidants and antioxidants in 
patients with COPD. A study of Daga et al.74 showed that supplementation of vitamin 
E could reduce the level of systemic oxidative stress in patients with COPD. However, 
very recently, high doses of vitamin E supplements have also been  associated with 
an increased risk of death.75 Next to the addition of antioxidants, decreasing the 
production of oxidants would be another possible target to reduce oxidative stress. 
Heunks et al.46 showed that xanthine-oxidase plays a role in the exercise-induced 
radical production in patients COPD. Short treatment with allopurinol (inhibitor 
of xanthine-oxidase) could prevent the exercise-induced glutathione oxidation and 
reduced the peroxidation of lipids. Whether allopurinol can also normalize the basal 
increased level of oxidative stress in COPD patients is unknown. Currently, effective 
antioxidants for clinical use that do not infl uence other physiological processes, 
like microbiological defenses, are now in development.76-78 Preventing oxidative 
stress and thereby avoiding free radical-mediated tissue damage in, for example, 
skeletal muscle might contribute to a better exercise capacity in patients with COPD. 
However, for now, too little evidence and knowledge about the safety of the use of 
supplements exists to make a statement about the general use of these therapies.
Additionally, several new treatments targeting the infl ammatory process are now 
in clinical development.79 A broad spectrum of anti-infl ammatory drugs is being 
investigated, including targets against infl ammatory cytokines and cell signaling 
inhibitors. In the meantime, there is still a lot of discussion about benefi ts and side 
effects of both oral and inhalation corticosteroids in the treatment of COPD. For a long 
time it was suspected that inhalation of corticosteroids could avoid systemic effects. 
Cameron et al.80 found a comparable systemic effect on the number of circulating 
leukocytes (neutrophilia and lymphopenia) with a high dose of inhalation steroids 
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(beclomethasone dipropionate 1000 μg) and a lower dose of oral steroids (prednisone 
2.5 mg). Furthermore, Sin et al.81 have recently shown that both oral administration 
and inhalation of fl uticasone (30 mg/day and 1000 μg/day, respectively) were 
effective in reducing serum C-reactive protein levels in patients with COPD. 
At this moment, we have to conclude that the basic systemic abnormalities in COPD 
patients are poorly understood. Because of the complexity and interplay between 
multiple effects, causes and consequences are still diffi cult to defi ne, which makes it 
diffi cult to fi nd targets for effective and safe pharmacological therapies. 
Training
Several large-scale randomized studies have demonstrated that pulmonary 
rehabilitation improves exercise performance and health status in COPD patients.82 
Additionally, one of the systemic effects, namely peripheral muscle weakness, has 
shown to improve after rehabilitation. It remains uncertain whether pulmonary 
rehabilitation affects exacerbation frequency, disease progression, mortality or the 
systemic effects, like infl ammation and oxidative stress. Very recently, promising 
data about the reduction in exercise-induced oxidative stress after 8 weeks of 
rehabilitation in 11 patients with COPD were published.12 However, others 42;83 have 
reported that, compared with healthy elderly people, patients with COPD showed 
a reduced ability to adapt to endurance training refl ected in a lower capacity to 
synthesize reduced glutathione and an increased TNF-α expression. The effect of 
repeated exercises and the addition of pharmacological therapies on these parameters 
would be interesting. Very recently, Broekhuizen et al.84 reported that the addition 
of supplemental polyunsaturated fatty acids (PUFA) to a pulmonary rehabilitation 
program improved the exercise capacity in COPD patients more than rehabilitation 
exclusively. Although PUFA can modulate local and systemic cytokine biology, 
the positive effects of PUFA on the exercise capacity could not be attributed to a 
decrease in systemic infl ammation in this study. A PUFA-induced decrease in 
local infl ammation could not be excluded. Therefore, further research to elucidate 
the mechanism behind the improved exercise capacity after PUFA intervention is 
needed. Additionally, it remains to be investigated whether PUFA intervention alone, 
without exercise training, will have a similar effect on exercise capacity in patients 
with COPD.
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Conclusions
Besides pulmonary involvement, COPD is associated with systemic effects. Low-
grade systemic infl ammation and oxidative stress are present and abnormally 
increase in response to exercise. These processes may have harmful effects by 
inducing damage to local organs and tissues or by negatively infl uencing the immune 
system. A better understanding of the complexity of the systemic effects will aid the 
development of new therapies and management strategies for patients with COPD.
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Abstract
Systemic infl ammation may be present in patients with chronic obstructive 
pulmonary disease (COPD). Exercise is known to elicit an infl ammatory response. 
We hypothesized that the systemic infl ammatory response to exercise might be 
exaggerated in COPD patients compared to healthy subjects. Sixteen COPD patients 
and eleven healthy subjects performed a maximal incremental bicycle test. Before 
and at maximal exercise arterial blood samples were taken to determine circulating 
catecholamines, (subsets of) leukocytes, acute phase proteins, creatine kinase and 
myoglobin. At rest, increased levels of norepinephrine and systemic infl ammation 
were present in COPD. The response of catecholamines to exercise was lower in 
COPD patients (p<0.01), which in part was due to the lower maximal exercise 
capacity of these patients (p<0.01). Exercise-induced leukocytosis showed similar 
responses in both groups, but occurred at higher levels in COPD. Although patients 
had increased levels of CRP at rest (p<0.001), exercise did not affect acute phase 
proteins. No systemic signs of muscle damage were found. The present study 
shows that COPD patients are exposed to systemic infl ammation that is intensifi ed 
by exhaustive exercise. The infl ammatory response in COPD is not exaggerated 
compared to healthy subjects but occurs at a higher level and is observed at lower 
external workload.
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Introduction
Considerable evidence links chronic obstructive pulmonary disease (COPD) with 
systemic infl ammation, 1;2 including altered numbers 3 and functions of circulating 
infl ammatory cells 4-6, cytokines 
7;8
, acute phase proteins 
3;7, and oxidative stress.9;10 
This indicates that COPD is not restricted to pulmonary disease, but may also affect 
distant organs, e.g. by inducing substantial skeletal muscle alterations 11 and weight 
loss.7 These factors may contribute to exercise limitation 12;13 and reduced quality of 
life in these patients.14 Exercise may be benefi cial for patients with COPD, in part 
by improving exercise tolerance (endurance and maximal exercise capacity), and 
training of muscles.15 On the other hand, it is known that exercise, if suffi ciently 
intense, leads to a highly stereotyped immune response in healthy subjects, mediated 
by an interplay of infl ammatory cells, hormones, cytokines, neural and hematological 
factors 16, that can also affect distant organs.17 Also, in subjects with cystic fi brosis 
it was found that low intensity exercise could increase already elevated circulating 
cytokines.18 Since COPD patients may show signs of systemic infl ammation, elevated 
levels of circulating catecholamines, marked sympathetic activation 19;20 and muscle 
wasting 21 at rest, it may be expected that physical activity will further increase 
these mediators. Indeed, recently it was shown that moderate intensity exercise in 
COPD abnormally increased plasma tumor necrosis factor-alpha (TNF-α) levels.22 
Moreover, exercise induces systemic 23;24 and muscle 25 oxidative stress in COPD 
patients. In view of these data, we hypothesized that exercise causes an exaggerated 
systemic infl ammatory response in COPD patients compared with healthy subjects, 
which consequently might worsen the effects on distant organs.
The purpose of this study was to characterize the effects of a single bout of exhaustive 
exercise on the systemic responses in COPD patients. Therefore, levels of circulating 
catecholamines and (subpopulations of) leukocytes as well as serum levels of acute 
phase proteins (CRP) and the muscle proteins creatine kinase (CK) and myoglobin 
(Mb) were measured before and after maximal incremental cycle ergometry.
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Methods
Subjects
Sixteen (10 males, 6 females) non-smoking COPD patients (age 52 to 68 yr) from 
our outpatient clinic participated in this study. These patients had moderate to very 
severe COPD (FEV1 23-68 % predicted) according to Global Initiative for Chronic 
Obstructive Lung Disease.26;27 They were free of exacerbations for at least two months 
prior to the study. Exclusion criteria were use of oral corticosteroids, long-term 
oxygen therapy, and other exercise-limiting diseases. Inhaled corticosteroids (ICS) 
(if used) were stopped one week prior to exercise testing (ten patients). All patients 
used inhaled bronchodilators (ipratropiumbromide and/or β2 –agonists), and none 
used theophylline. The patients were recruited before going through a rehabilitation 
program. For the control group, 11 males, 2 females) non-smoking, sedentary 
healthy subjects (age 47 to 64 yr) were recruited from the social environment of the 
patient group. The study was conducted according to the Declaration of Helsinki and 
approved by the medical ethical committee of our hospital. Written informed consent 
was obtained from all subjects.
Pulmonary function
Standard pulmonary function tests including spirometry, static lung volumes 
and diffusing capacity for carbon monoxide (DLCO) were obtained prior to cycle 
ergometry.
Protocol Cycle Ergometry
All subjects performed a maximal, symptom limited, incremental exercise test. They 
cycled on an electrically braked cycle ergometer (Masterlab, Jaeger, Würzburg, 
Germany) at a pedaling rate of 60 rotations min-1 breathing room air. The workload 
was increased every minute by 10% of estimated maximum work capacity (Wmax) 
until exhaustion. The maximum work capacity was calculated according to the 
equitation of Jones et al.28 This maximal value was then adapted to the subject by 
multiplying it by FEV1/FEV1 predicted.
29 The exercise protocol resulted in a test 
duration of 8 to 12 minutes, which meets the exercise testing recommendations.30 
Minute ventilation ( E), oxygen consumption ( O2) and carbon dioxide production 
( CO2) were measured every 30 seconds breath-by-breath (Oxyconbeta, Mijnhardt/
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Jaeger, Bunnik, The Netherlands). Electrocardiography (ECG) was conducted 
throughout the test and saturation was measured using a pulse-oxymeter (Datex, 
Helsinki, Finland). If ECG-changes or chest pain occurred, or saturation fell below 
85%, the test was stopped immediately. Blood pressure was measured every two 
minutes during the test.
Collection of blood samples
A cannula was inserted into the brachial artery under local anesthesia to obtain arterial 
blood. Arterial blood samples were collected at rest, every 3 minutes during exercise, 
at Wmax and 3, 30, 60 and 120 min after the test. Two hours after the exercise testing 
the arterial cannula was removed. Venous blood was collected via a venapuncture at 
6h and 24h after the test for determination of muscle damage markers (see below). 
Measurements after exercise were corrected for plasma volume shifts according to 
Dill and Costill.31
Analytical procedures
Blood for determination of hemoglobin, hematocrit, CRP (ELISA, detection limit 
1 μg·ml-1) and leukocytes was collected (at rest, Wmax, and 30, 60 and 120 minutes 
after exercise) in vacutainers containing EDTA and analyzed immediately according 
to standard laboratory assays. To determine CK, Mb, uric acid, and glucose, blood 
was collected in dry vacutainers and analyzed immediately in serum according to 
standard laboratory assays.
For blood gas and lactate analysis, arterial blood was collected in special heparinized 
syringes and analyzed immediately (Gas analyzer Chiron 860). Blood gasses (PaO2, 
PaCO2) were measured pre-exercise, every 3 minutes during the exercise and 3 minutes 
after maximal work rate. Lactate levels were determined enzymatically at rest and 3 
minutes after maximal exercise.
Catecholamine measurement
Blood was collected at rest, directly after maximal exercise and after 30 minutes of 
recovery in pre-cooled vacutainers containing heparin. Blood samples were put on 
ice and spun down immediately. Supernatant was stored in tubes containing 0.25 
mol·l-1 EGTA and 0.2 mol·l-1 glutathione in distilled water (pH 7.4). Epinephrine and 
norepinephrine were measured according to Willemsen et al.32
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Phenotype analysis of peripheral blood mononuclear cells (PBMC)
Blood samples for lymphocyte immunophenotyping by three-color fl ow cytometry 33 
were collected at rest, Wmax and 30, 60 and 120 minutes after exercise in heparinized 
vacutainers. Monoclonal antibodies with a fl uorescing label were used to identify the 
numbers of helper/inducer T-lymphocytes (CD3+/CD4+), B-lymphocytes (CD19+) 
and natural killer (NK) cells (CD3-/CD56+/CD16+).
Statistics
Differences in baseline values, anthropometric variables and pulmonary function 
between healthy subjects and patients with COPD were determined with two-sample 
t-tests and Mann Whitney U tests (if the normality assumption (Kurtosis) was not 
obtained). Repeated measures analysis of variance (ANOVA) was used to analyze all 
responses to the maximal exercise bout. Between-subject tests were used to compare 
overall response differences between the control and COPD group across the time 
points (between-group effect). Single degree of freedom orthogonal polynomials 
over time were used to characterize possible changes caused by exercise, i.e. linear 
and quadratic changes across time (time effect). These polynomials were examined 
for absolute values with all time points and for differences from baseline (for each 
subject). A difference between the control and the COPD group in the response 
pattern by exercise was tested using the interaction between each polynomial and 
the between subject factors (time*group effect). Linear regression analysis was 
performed to test if exercise capacity, catecholamine response, and lymphocyte 
response were correlated.
Statistical signifi cance was taken at the p<0.05 level. Results are presented as means 
± SE. Data were analyzed with SPSS/PC+, version 12.0 (SPSS, Chicago, IL).
Results
Anthropometric and pulmonary function data
Subjects’ characteristics and pulmonary function data are provided in Table 1. Age 
and body mass indices (BMI) were similar in both groups. The main differences were 
observed in pulmonary function where the COPD group showed moderate to very 
severe airfl ow obstruction. There was no signifi cant difference in arterial oxygen or 
carbon dioxide tension between the groups. None of the subjects were hypoxemic at rest.
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Data are expressed as means ± SE. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in fi rst second; VC, vital 
capacity; TLC, total lung capacity; DlCO, diffusion capacity for carbon monoxide; PaO2, arterial oxygen 
tension PaCO2, arterial carbon dioxide tension; pred, predicted value.
*** p<0.001 versus healthy subjects.
Catecholamines and systemic infl ammation at rest
As shown in Figure 1, there was no signifi cant difference in plasma epinephrine levels 
at rest between COPD patients and healthy subjects. Baseline norepinephrine levels, 
however, were signifi cant higher (p<0.05) in COPD patients. Systemic infl ammation 
at rest was indicated by increased numbers of total circulating leukocytes (p<0.05), 
neutrophils (p<0.05), and monocytes (p<0.05) as well as enhanced CRP levels 
(p<0.001) in COPD patients. No signifi cant differences between COPD patients 
and healthy subjects were measured in numbers of circulating lymphocytes and the 
subsets NK-cells, T- and B-lymphocytes. 
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Figure 1. Individual and mean values of baseline epinephrine, norepinephrine, circulating leukocytes, 
neutrophils, monocytes, and CRP in healthy subjects and patients with COPD.
* p<0.05, *** p<0.001 versus healthy subjects. 
Maximal exercise test
Physiological data
Physiological responses to exercise are shown in Table 2. As expected, Wmax was 
signifi cantly lower in COPD patients (p<0.001). Also, duration of the exercise 
test, maximal oxygen uptake (peak O2) and minute ventilation (peak E) were 
signifi cantly lower in the COPD group. The peak E, however, represented 96 ± 
6% of the maximal voluntary ventilation (MVV) in COPD patients and 68 ± 4% in 
the control group (p<0.01). PaO2 signifi cantly decreased during exercise in COPD 
patients (p<0.05), while PaCO2 increased (p<0.001). Six patients became hypoxemic 
and fi ve became hypercapnic during exercise. No changes in PaO2 occurred in healthy 
subjects, while PaCO2 decreased at maximal exercise (p<0.01). In both groups, a 
signifi cant increase (p<0.01) in plasma lactate was observed at Wmax. This increase 
of lactate levels was signifi cantly lower in COPD patients compared with healthy 
subjects (Δ lactate; 4.1 ± 0.7 mM vs. 7.3 ± 0.9 mM, p<0.05).
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Data are expressed as means ± SE. 
Abbreviations: Wmax, maximal work capacity; Endurance, duration of exercise test; HR, heart rate; 
peak  O2, maximal oxygen consumption; E, minute ventilation; MVV, maximal voluntary ventilation; 
PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; pred, predicted. 
** p<0.01, *** p<0.001 versus healthy subjects.
Catecholamines
Plasma levels of epinephrine and norepinephrine before and after the exercise test 
are shown in Figure 2. Exercise led to signifi cant changes in plasma epinephrine and 
norepinephrine in both groups (p<0.001 for both catecholamines). The response to 
exercise was signifi cantly lower in COPD patients compared with healthy subjects 
for both catecholamines (p<0.05 for epinephrine, and p<0.001 for norepinephrine). 
The plots in Figure 3 show that the lower response of catecholamines to exercise 
in COPD patients was related the relative lower work intensities they performed. 
Also, within the COPD group, Wmax and peak O2 were positively correlated with 
changes in norepinephrine (r = 0.60, p<0.05 and r = 0.57, p<0.05 respectively). As 
described above, basal levels of norepinephrine were signifi cantly higher in COPD 
patients compared with healthy subjects (p<0.01). To exclude infl uence of inhaled 
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β2- agonists on catecholamine levels, a subgroup of six COPD patients was asked 
to stop the inhalation of β2-agonists for one week and to perform a second maximal 
exercise test after this period. Discontinuation of inhaled β2-agonists in these patients 
for one week did not affect maximal exercise capacity nor levels of catecholamines 
at rest (epinephrine, p=0.64; norepinephrine, p=0.73), or at Wmax (epinephrine, 
p=1.0; norepinephrine, p=0.74), see Table 3.
Figure 2. Effects of exercise on plasma concentrations epinephrine (A) and norepinephrine (B) in both 
healthy subjects and patients with COPD. Exercise induced a signifi cant response of the catecholamines 
in both groups (p<0.001). Both epinephrine and norepinephrine responses were lower in COPD patients 
(p<0.05). 
Figure 3. Exercise-induced changes in norepinephrine levels related to maximal workload (A) and peak 
O2 (B) in healthy subjects and patients with COPD.
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Data are expressed as means ± SE. 
Abbreviations: Wmax, maximal work capacity; peak O2, maximal oxygen consumption
Numbers of total circulating leukocytes in both COPD patients and healthy subjects 
at rest, directly after exercise and during recovery are shown in Figure 4A. Maximal 
exercise caused an immediate increase of circulating leukocytes in both COPD 
patients (from 7.6 ± 0.7 to 9.2 ± 0.9 · 109 cells·l-1) and healthy subjects (from 5.4 ± 
0.2 to 7.4 ± 0.2 ·109 cells·l-1), followed by a rapid decrease during the fi rst 30 minutes 
of recovery and a second increase later in the recovery period (time effect: p<0.001). 
The mean numbers of leukocytes were signifi cant higher in COPD patients compared 
with healthy subjects (p<0.05), but the response to exercise was comparable in both 
groups (time*group effect: p>0.05). 
The exercise-induced response of leukocytes as caused by its subsets, is also 
shown in Figure 4. In all subsets, a signifi cant response to exercise was measured 
in both COPD patients and healthy subjects (p<0.001). The mean numbers of both 
neutrophils (Figure 4B) and monocytes (Figure 4C) before and after exercise were 
signifi cantly higher in COPD patients compared with healthy subjects (p<0.05 and 
p<0.01, respectively), but the responses (absolute and relative) to exercise were 
not different. As shown in the last panel of Figure 4 (4D), the absolute response of 
lymphocytes caused by exercise was signifi cant lower in COPD patients compared 
with healthy subjects (p<0.001). 
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Figure 4. Effects of exercise on circulating leukocytes and subsets in both healthy subjects and patients 
with COPD. Exercise caused signifi cant responses of total leukocytes (A), neutrophils (B), monocytes 
(C), and lymphocytes (D) in both groups. Responses of leukocytes and the subsets neutrophils and 
monocytes were similar in patients and healthy subjects. Lymphocyte response was signifi cantly lower 
in COPD patients (p<0.001).
In addition to this fi nding, signifi cant correlations (p<0.001) were found between 
exercise capacity, catecholamine response, and lymphocyte response (Figure 5). 
Furthermore, within the COPD group, peak O2 was correlated with changes in 
lymphocytes (r = 0.57, p<0.05), and changes in norepinephrine were related to the 
lymphocyte response (r = 0.54, p<0.05). Evaluation of the exercise-induced response 
of the NK-cells and lymphocyte subsets resulted in similar responses for COPD 
patients and healthy subjects. NK-cells (Figure 6A) and B-lymphocytes (Figure 
6B) resembled the response of the total lymphocytes, although the reduction in the 
responses of COPD patients was not signifi cant here. The  response of T-lymphocytes 
immediately after maximal exercise was the same in both groups (Figure 6C). 
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The difference occurred after two hours recovery when the T-lymphocytes of COPD 
patients were still elevated from baseline levels (p<0.01).
Figure 5. The infl uence of exercise capacity (A) and subsequent changes in norepinephrine (B) on 
lymphocyte response to exercise. 
Figure 6.  Effects of exercise on circulating NK cells and lymphocyte subsets in both healthy subjects 
and patients with COPD. The responses of NK-cells (A) and B-lymphocytes (B) to exercise was 
comparable in both groups, while the pattern of the response of the T-lymphocytes (C) differed between 
the groups after two hours of recovery (p<0.01).  
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Discontinuation of β2-agonists in a subset of COPD patients did not affect numbers 
of (subsets of) leukocytes at rest (p=0.3), or after maximal exercise (p=0.8), see 
Table 3. Plasma levels of CRP after exercise did not differ from rest values in both 
COPD patients and healthy subjects.
Muscle damage markers
As shown in Table 4, serum levels of the muscle damage markers CK and Mb did not 
differ between COPD patients and healthy subjects at rest (p=0.4) and did not change 
signifi cantly in response to short exhaustive bicycle exercise.
Data are expressed as means ± SE. 
Abbreviations: CK, creatine kinase; Mb, myoglobin. 
No signifi cant differences between the groups or in response to exercise were observed.
Discussion
The present study shows that the exercise-induced systemic infl ammatory response 
is not exaggerated in COPD patients compared with healthy subjects. The systemic 
infl ammatory response to exhaustive exercise at relatively low external workload in 
COPD patients is comparable with the response to high intensity maximal exercise 
in healthy subjects, but occurs at a higher level in COPD. Therefore, the absolute 
number of circulating infl ammatory cells is intensifi ed to higher levels in patients with 
COPD, which may stimulate several infl ammatory mediators and processes. Due to 
lower exercise intensity, catecholamine response was lower in COPD patients. These 
data indicate that patients with COPD performing strenuous exercise are exposed to 
an intensifi ed systemic infl ammation.
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Catecholamines
In response to exercise above 60% of peak O2, plasma concentrations of a number 
of stress hormones, including epinephrine and norepinephrine, increase and return 
to prevalues shortly after exercise.34 Discharge from sympathic splanchnic nerves 
and innervation of the adrenal medulla result in the release of epinephrine and 
norepinephrine into the plasma immediately after start of intense muscular exercise. 
These stress hormones have marked physiological effects on heart rate and vasomotor 
tone, and ultimately on blood fl ow through lymphoid tissues and leukocyte circulation 
patterns.35 In the present study, plasma catecholamine levels indeed increased during 
maximal exercise in both COPD patients and healthy controls and declined rapidly 
after exercise. Catecholamines increase almost linearly with the duration of exercise 
and exponentially with intensity, when it is expressed relative to individual’s peak 
O2.
36 The lower catecholamine levels of COPD patients at maximal exercise 
compared with healthy controls in this study can at least partially be explained by 
the lower exercise capacity (both ventilatory capacity and maximum workload) of 
the patients or by the shorter duration of their exercise, as is illustrated when exercise 
capacity is plotted against changes of noradrenaline (Figure 3). Debigare and 
coworkers 37 showed that a greater increase in the cycling load during an incremental 
exercise test resulted in higher achieved peak loads. According to them, peak O2, 
however, was independent of the increase in workload. Because the catecholamine 
response was not only correlated with Wmax in the present study, but also with peak 
O2, we think that our results were not infl uenced by the different exercise protocols. 
Furthermore, the study was not designed to compare the increases of catecholamine 
levels between the groups at isotime or isoworkload exercise between COPD patients 
and healthy subjects. If the increases in cycling load had been similar in patients 
and healthy subjects, probably the exercise recommendations of 8 to 12 min test 
duration 30 were not met. Based on our results at maximal exercise, it is suggested 
that the catecholamine response to exhaustive exercise is not affected by COPD. 
These results are in disagreement with data of Colice et al.38 , who reported that the 
rate of increase of epinephrine (but not norepinephrine) with maximal exercise was 
smaller in hypoxic COPD patients than in healthy controls. Their fi ndings supported 
the concept that (chronic) hypoxia interferes with the adrenal medullary response 
to exercise. In our study, most of the COPD patients remained normoxic during 
exercise, which may explain the difference between these studies.
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Remarkably, plasma levels of norepinephrine at rest were higher in COPD patients 
compared with healthy subjects in our study. Other investigators also found elevated 
baseline values of (nor-) epinephrine in (a subgroup of) COPD patients.38;39 The 
precise mechanism of these fi ndings is unclear. Beta2-adrenoreceptor agonists, 
used by many COPD patients, produce a number of metabolic changes.40 In a study 
of Malerba et al.41, plasma norepinephrine concentrations of COPD patients using 
systemic β2-agonists were signifi cantly increased at rest and especially during 
cardiopulmonary exercise test, due to activation of the orthosympathetic nervous 
system and anaerobic metabolism. This possible β2-effect was ruled out in our study 
because a subgroup of patients performed a second test after discontinuation of their 
use of inhaled β2-agonists for one week. Discontinuation of these β2-agonist caused 
no differences in catecholamine levels at rest or after exercise testing.
Systemic infl ammation
The earliest and most consistent observation of the exercise-immune interaction has 
been the so-called “leukocytosis of exercise”.42 Despite variation in type, intensity, 
duration of the exercise, and fi tness level of the subjects, several consistent patterns 
emerge regarding the leukocyte subpopulations in blood. The leukocytosis in both 
COPD patients and healthy controls in the present study refl ected the previously 
described patterns: an early leukocytosis characterized mainly by an increase in all 
subsets, followed by a second phase during which neutrophils gradually increased 
and lymphocytes concentrations rapidly fell down. This typical infl ammatory 
response of total leukocytes and the subsets neutrophils and monocytes had a similar 
pattern in COPD patients and healthy subjects, but occurred on an elevated level in 
the patients. Acute lymphocytosis also occurred following maximal exercise in all 
subjects, but the increase in lymphocytes, especially B-lymphocytes, and NK-cells 
was impaired in COPD patients (only signifi cance in total lymphocytes). Absence 
of signifi cant differences in B-lymphocytes and NK-cells can partly be attributed to 
relative large interindividual variability that is known in these cells 43, which results 
in large standard errors seen in the present study. According to different models 
35;42;44, catecholamines are responsible for the acute exercise-effects of lymphocyte 
subpopulations and NK-cells. Finding less increase in levels of catecholamines 
in COPD patients (due to relative low intensity exercise) supports our results of a 
slightly decreased lymphocytosis in these patients (Figure 5). T-lymphocyte response 
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of COPD to exercise resembled the response of controls, except for the remained 
elevation of T-lymphocytes of COPD patients after 2h.
With stopping the use of ICS, if used, one week prior to the study, possible declining 
effects of ICS on systemic infl ammatory markers 45;46 were prevented. Again, any 
possible effect of β2-agonists 
47 on different leukocyte counts can be ruled out because 
patients, who stopped the inhalation of these agonists, did not show any difference in 
leukocyte baseline levels or levels after the maximal exercise test.
Although COPD patients had increased basal levels of CRP compared with healthy 
subjects, exercise did not change the levels in both groups. Serum levels of acute phase 
reactants do change with infl ammation 48, but with respect to exercise models, the 
serum levels of these reactants have not been well characterized. To our knowledge, 
no data are reported about CRP levels after exercise in COPD patients. While Pyne 
et al.49 published no changes in CRP after 40 minutes uphill (90 % of peak O2) or 
downhill (52% of peak O2) running in healthy subjects, Mastaloudis et al.
50 recently 
demonstrated remarkable increases in CRP in ultra marathon runners (423 minutes, 
71% of peak O2) . Additional research on the impact of exercise on acute phase 
reactants is needed.
Limitations
In the present study, the gender distribution is different between the two study groups. 
Although there is no consensus in the literature, some data 51 suggest that there may be 
gender-based differences in muscle damage, infl ammation and oxidative stress after 
exercise, possibly caused by estrogen. Because all females included in the presented 
study were postmenopausal, the possible effect of estrogen can be minimized. In 
addition, Moyna et al.52 showed that the alterations in the numbers of circulating 
leukocytes during and following an acute progressive incremental exercise test (3 
periods of 6 min cycling at 55, 70, and 85% of peak O2) are independent of gender. 
Therefore the exercise-induced infl ammatory responses found in this study are 
probably not affected by gender differences. 
Leukocyte source
The source of the leukocytes mobilized during exercise and what mechanisms are 
involved in the mobilization were not subject of this study but are of considerable 
interest. It is clear that the immediate mobilized cells are derived from the 
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marginated or non-circulating leukocyte pool(s), while the delayed (second) increase 
of leukocytes after two hours (especially neutrophils) can also be infl uenced by 
release of (immature) cells from the bone marrow. Less clear is the place in the body 
where the pool for the immediate response is located. The spleen, the lungs, and 
the peripheral blood vessels seem important candidates.16;42 Whether the source(s) 
of exercise-induced leukocytosis or the mechanism(s) involved in this mobilization 
differs between healthy subjects and COPD patients, is not known yet. Speculatively, 
the lungs might play a more important role in the leukocytosis of COPD patients 
compared to healthy subjects because pulmonary infl ammation causes increased 
levels of neutrophils and lymphocytes in the lungs.
Markers of muscle damage
Muscular exercise commonly results in injury to fi bers in the active muscles, 
particularly when the exercise is relatively intense (>60% of peak O2), of long 
duration (>30 minutes) and/or includes eccentric contractions.11;53 One of the clinical 
symptoms associated with muscle injury includes elevated plasma levels of muscle 
proteins (e.g. CK and Mb). In the presented study, no evidence of muscle damage 
was found systemically in COPD patients or in healthy subjects after a short bout 
of maximal exercise. Both groups did not show changes in circulating levels of 
CK and Mb after exercise. The mechanism of metabolic stress, characterized by 
disturbances in cellular metabolism, has been proposed to explain muscle damage 
after prolonged (>30 min) high intensity or exhaustive exercise.11 Metabolic stress 
not only induces muscle damage, but also activates the hormonal and infl ammatory 
response to repair tissue damage. Several explanations for not fi nding evidence of 
muscle damage are possible. Firstly, changes in plasma levels of muscle proteins 
are related to membrane (sarcolemmal) damage or permeabilization. Absence of 
changes in these proteins does not exclude injury of sarcomere or other organelles 
(e.g. mitochondria). Using muscle proteins in blood as marker for muscle damage 
has been criticized by many authors.54 Some of them even conclude that muscle 
damage can never be correctly estimated by any marker in circulating blood because 
these markers are always a refl ection of the difference between release and uptake 
by other tissues.55 Secondly, we did not assess muscle injury or damage directly. And 
fi nally, the duration of the exercise test, especially in COPD patients could have been 
too short to induce markedly muscle damage. For these reasons, defi nite conclusions 
about muscle damage cannot arise from the present fi ndings.
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Clinical Relevance
Mechanisms and consequences of systemic infl ammation are still poorly understood. 
So far, it is thought that systemic infl ammation may be associated with nutritional 
abnormalities, weight loss, skeletal muscle dysfunction and subsequently exercise 
tolerance in patients with COPD.1 Increased numbers of leukocytes and also pre-
activation of these cells, especially monocytes and neutrophils, have been reported 
in earlier studies with stable COPD patients.2 Changes in the numbers and functions 
of these cells may be of relevance for the normal process of neutrophils clearance 
by macrophages from infl amed tissues.4;56;57 High levels of circulating leukocytes 
will also affect production of infl ammatory mediators and reactive oxygen species, 
which together play an important role in the regulation of systemic infl ammatory 
response and the possible effects on distant organs. Circulating lymphocytes have 
been less well studied than circulating neutrophils in patients with COPD. There are 
some indications of abnormal lymphocyte function in these patients 58, but whether 
these issues infl uence patient’s defense against infl ammation, remains to be resolved. 
Although the present study shows that the exercise-induced leukocytosis in COPD 
patients is not different from healthy subjects, two important aspects have to be 
kept in mind. Firstly, the patterns of the leukocytosis are not different between the 
groups, but the absolute numbers of the infl ammatory cells in COPD patients rise to 
rather high levels. These levels probably also affect other parts of the infl ammatory 
cascade, which together contribute to a further increase of systemic infl ammation. A 
second concern is the comparison of exercise tests of healthy subjects and ventilatory 
limited patients. Unlike healthy subjects, patients with COPD become exhausted 
at low external workload; for instance during daily life activities, which therefore 
may result in a more frequent exposure to systemic infl ammation. During daily life 
activities, patients with COPD reach a O2 of 8-10 ml·kg
-1·min-1.59;60 In the present 
study, however, a standardized maximal exercise protocol was used, resulting in a 
mean peak O2 of 17 ml·kg
-1·min-1 in the COPD patients. Therefore, further studies 
are needed to investigate if submaximal exercises and daily life activities also leads 
to an increase of systemic infl ammation as shown in the present study.
In summary, the present study shows that exercise-induced systemic infl ammatory 
response is not exaggerated in COPD compared with healthy subjects, but occurs 
on higher levels in COPD. Unlike healthy subjects, COPD patients become easily 
exhausted during daily life by using a relative high percentage of their Wmax and 
peak O2. Recurrent exhaustion and fatigue may therefore result in frequent exposure 
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to intensifi ed levels of systemic infl ammation that may also affect several distant 
organs. In these patients, an association exists between systemic infl ammation, 
metabolic derangement 61, oxidative stress and skeletal muscle dysfunction.1 These 
processes further enhance the extrapulmonary effects of COPD by positive feedback 
mechanisms and autocrine functions and, thus, may maintain the vicious cycle of 
COPD, systemic effects and inactivity. Future investigations are needed to further 
clarify the exercise-induced infl ammatory response in COPD patients and its 
(systemic and local) clinical consequences in view of treatment of these patients.
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Abstract
Physical exercise is known to induce an acute infl ammatory response and oxidative 
stress in healthy subjects and patients with chronic obstructive pulmonary disease 
(COPD). Increasing evidence associates systemic infl ammation and oxidative stress 
with muscle wasting and muscle dysfunction in COPD. In the present study, it was 
hypothesized that exercise-induced systemic infl ammatory and oxidative responses 
in muscle-wasted COPD patients are increased compared to non-muscle wasted 
patients and healthy subjects. 
Pulmonary function, body composition, and quadriceps muscle strength were 
measured in 10 muscle-wasted (fat free mass index (FFMI) <16 kg·m-2 (men), 
<15 kg·m-2 (women)) and 10 non-muscle-wasted COPD patients, and 10 healthy 
subjects. Systemic infl ammation (C-reactive protein, CRP; leukocytes; cytokines) 
and oxidative stress (production of reactive oxygen species (ROS) by neutrophils; 
plasma antioxidant capacity; protein oxidation; lipid peroxidation; oxidized-to-
reduced glutathione ratio, GSSG/GSH) were determined before and after maximal 
and submaximal (50% of maximal work rate) cycle ergometry. 
Low-grade systemic infl ammation was signifi cantly (p<0.05) elevated in all COPD 
patients and tended to be highest in muscle-wasted patients. A decreased antioxidant 
status (plasma antioxidant capacity, p<0.05 and GSH, p<0.05) and increased protein 
oxidation (p<0.001) refl ected  increased basal oxidative stress in muscle-wasted 
COPD patients compared to both other groups. Both maximal and submaximal 
exercise caused increased infl ammatory (IL-6, +1.1 pg·ml-1 versus rest, p<0.05) and 
oxidative responses (ROS release by neutrophils, + 32%; GSSG/GSH + 29%; lipid 
peroxidation, +30% versus rest) in muscle-wasted COPD patients, which were less 
pronounced or not observed in non-muscle-wasted patients and healthy subjects. 
These data indicate that both maximal and submaximal exercise induce increased 
systemic infl ammatory and oxidative responses in muscle-wasted COPD patients 
compared with non muscle-wasted patients and healthy subjects.
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Introduction
Physical exercise is known to induce an increased production of reactive oxygen 
species (ROS), and an acute infl ammatory response in healthy subjects.1;2 In patients 
with chronic obstructive disease (COPD), studies have shown that different types 
of physical exercise (e.g. cycling and localized quadriceps exercise) result in 
systemic and muscle oxidative stress.3-5 Furthermore, two studies have suggested 
that exercise induces abnormal systemic infl ammatory responses in COPD.6;7 The 
exact meaning of systemic infl ammation and oxidative stress in COPD has not been 
elucidated, yet and may be multi-factorial, but both processes have increasingly been 
recognized to play a role in loss of muscle mass and muscle dysfunction.8 Weight 
loss and muscle wasting have been reported in approximately 20% of stable COPD 
patients and have been inversely related to physical performance, susceptibility to 
exacerbations and outcome prognoses.9 Increased levels of circulating infl ammatory 
cells, cytokines (interleukin (IL)-6, -8, and tumor necrosis factor-α (TNF-α)), and 
acute phase reactant protein (C-reactive protein (CRP)) have been reported in 
stable COPD patients at rest, all refl ecting a low grade of systemic infl ammation 
in these patients.7;10 Different investigations have associated systemic infl ammatory 
mediators and muscle wasting 11;12,  supporting the concept of harmful peripheral 
effects of infl ammation in COPD. Furthermore, infl ammation may affect peripheral 
tissues and organs by inducing oxidative stress. Infl ammatory mediators reduce 
the level of antioxidants, and increase generation and release of reactive oxygen 
species (ROS) by mitochondria and neutrophils.13 Inversely, oxidative stress itself 
can enhance infl ammation through activation of redox-sensitive transcription factors 
that regulate the gene expression for infl ammatory mediators.14 Since both oxidative 
stress and infl ammation can induce substantial harmful effects to cells and tissues, 
they may together be implicated in muscle wasting and –dysfunction. However, no 
data about basal and exercise-induced systemic infl ammation and oxidative stress in 
especially muscle-wasted COPD patients have been reported, yet.
The present study describes basal and exercise-induced systemic oxidative stress and 
acute infl ammatory response in healthy subjects, non-muscle wasted COPD patients, 
and muscle-wasted COPD patients, expecting to fi nd increased infl ammatory and 
oxidative responses in the latter group. 
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Methods
Subjects
Twenty ex-smoking COPD patients 24 and ten non-smoking healthy subjects 
participated in this study. The patients were recruited from our outpatient clinic 
and prestratifi ed into two groups: patients with a normal body composition (non-
muscle-wasted) and patients with a decreased fat free mass index (muscle-wasted 
patients: men, FFMI <16 kg·m-2; women, FFMI <15 kg·m-2 ).9 The healthy control 
group consisted of relatives and friends of the patients, living in the same area. All 
participants were ex-smokers who stopped at least one year before inclusion (non-
muscle-wasted, 47 ± 7 pack years; muscle-wasted 43 ± 5 pack years, and healthy 
subjects, 39 ± 6 pack years). Exclusion criteria were exacerbations within the last 
two months prior to the study, the use of oral corticosteroids, long-term oxygen 
therapy, and other chronic infl ammatory or exercise-limiting diseases. The use of 
inhaled corticosteroids (n=5), antioxidants or vitamins (n=4) was stopped two weeks 
prior to exercise testing since these therapies may infl uence the outcome parameters. 
All patients were on bronchodilator therapy, none used theophylline. None of the 
patients went through any rehabilitation program before inclusion. The study was 
conducted according to the Declaration of Helsinki and was approved by the medical 
ethical committee of our hospital. Written informed consent was obtained from all 
participants.
Study design
Pulmonary function, body composition, and quadriceps force were assessed as part 
of the characterization procedure. All subjects performed a maximal, incremental 
bicycle test until exhaustion. Subjects cycled on an electrical braked cycle ergometer 
(Masterlab®, Jaeger, Würzburg, Germany). In a subsequent visit (one week later) a 
submaximal constant work-rate bicycle test of 30 minutes at 50% of their maximal 
work rate (Wmax) was performed.15 On both exercise days, a cannula was inserted 
into the radial artery under local anesthesia to obtain arterial blood before, during 
and up to 30 minutes after the exercise. During blood sampling, patients were in 
sitting position for at least fi ve minutes. Measurements after exercise were corrected 
for plasma volume shifts (hydration status) according to Dill and Costill.16 Systemic 
infl ammation was characterized by measurements of plasma cytokines, circulating 
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leukocytes and serum CRP. The oxidative response was refl ected by measures of 
free radical production of neutrophils, plasma total antioxidant capacity, oxidation 
of proteins (carbonyl formation) and lipids (thiobarbituric acid reactive substances, 
TBARs), and both the reduced and oxidized form of glutathione (GSH and GSSG, 
respectively).
Pulmonary function
Static and dynamic lung volumes were measured using a spirometer (Masterlab®, 
Jaeger, Würzburg, Germany). Diffusion capacity for carbon monoxide (DLCO) and 
its capacity per unit of alveolar volume (KCO) were determined using the single 
breath method (Masterlab®, Jaeger, Würzburg, Germany). Maximal inspiratory 
and expiratory mouth pressures (Pimax, Pemax) were measured to evaluate respiratory 
muscle function (Masterlab®, Jaeger, Würzburg, Germany). 
Assessment of body composition
Besides body height and weight, body composition was assessed by a single 
frequency bioelectrical impedance analysis (Biostat 1500, Bodystat LTD, Douglas, 
Isle of Man, British Isles) in the supine position at the left side. Weight parameters 
were adjusted for body surface area to give body mass index (BMI) and FFMI. 
Peripheral muscle strength
Quadriceps muscle function was determined essentially as described previously.17 The 
subjects sat on an exercise bench, were strapped at the hips to prevent compensating 
movements, kept their arms crossed in front of the chest, bent forwards with their 
upper body and maintained their position during all contractions. A force transducer 
was strapped at 26 cm from the knee-joint space perpendicularly to the lower leg. The 
force transducers were connected to an amplifi er (Type CA660; Peekel instruments 
BV, Rotterdam, The Netherlands), linked to a personal computer to display force 
signals and for off-line analysis. The force during an isometric maximal voluntary 
contraction (MVC) was determined for the left and right quadriceps muscles. Thereto, 
the subjects were asked to perform an MVC for three seconds. The maximal force 
during an MVC was defi ned as the mean maximal force developed during a three 
second plateau. The highest value of the dominant leg (< 5% of variability within 
one leg) was defi ned as subjects’ MVC. 
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Exercise protocol
First, all subjects performed a maximal, incremental bicycle test until exhaustion, 
according to the criteria of the American Thoracic Society on cardiopulmonary exercise 
testing.18 Subjects cycled on an electrically braked cycle ergometer (Masterlab®, Jaeger, 
Würzburg, Germany) at a pedaling rate of 60 rotations⋅min-1 breathing room air. After 
unloaded pedaling for three minutes, the workload was increased every minute by 
5-20W until exhaustion. The rate of increase was calculated in order to reach the 
predicted maximal work rate (Wmax = predicted O2  – basal O2)/10) within 10 
minutes of exercise. During exercise, ventilation ( E), oxygen consumption ( O2) 
and carbon dioxide production ( CO2) were measured breath-by-breath (Oxyconbeta, 
Mijnhardt/Jaeger, Bunnik, The Netherlands), electrocardiography (ECG) was 
conducted, and saturation was measured using a pulse-oxymeter (Datex, Helsinki, 
Finland). Additionally, blood pressure was measured every two minutes during the 
test and Borg scores (0-10) for dyspnea and leg fatigue were obtained before and at 
maximal exercise. 
One week after the maximal exercise, all subjects performed a submaximal bicycle 
test at 50% of their Wmax on the same ergometer. After unloaded pedaling for three 
minutes, the work rate was increased up to the 50% Wmax level within one minute. 
At this workload, subjects continued cycling for 30 minutes. 
Blood gas and lactate analysis
Arterial blood gasses (PaO2, PaCO2) were obtained pre-exercise, every three minutes 
during exercise and three minutes after the end of the exercise in heparinized syringes 
(Bayer®, Massachusetts, USA). Lactate levels were determined enzymatically at rest 
and three minutes after exercise. Measurements occurred immediately after sampling 
(Gas analyzer Chiron 860).
Markers of systemic infl ammation
Arterial blood for measurement of plasma cytokines were obtained at rest, Wmax, 
and 30 min after exercise in ethylene diamine tetra-acetic acid (EDTA)-containing 
tubes and put on ice. Samples were centrifuged immediately (1000 g, 10 min, 4oC), 
and plasma was stored at –80oC until analysis. Analyses were performed using 
quantitative sensitivity and high-sensitivity sandwich enzyme-linked immunosorbent 
assays (ELISA) in kit form (R&D systems, Minneapolis, USA) according to the 
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supplier’s instructions. Detection limits for TNF-α, IL-1 receptor antagonist (ra), 
IL-6, and IL-8 were 0.12, 22, 0.039, and 2.5 pg/ml, respectively. Plasma levels of the 
samples were all above these limits. Inter- and intra-assay precision (coeffi cients of 
variances) for these markers were below 7%. 
Leukocyte counts and C-reactive protein (CRP) were determined at rest, Wmax, 
and 30 minutes after exercise. Leukocytes and its differentiation were counted with 
an automated analyzer (H*3 from Bayer (Tarrytown, New York, USA), and CRP 
was measured by standard turbidimetric analysis with a detection limit of 3 µg·ml-1. 
Assays were performed immediately after sampling.
Markers of the oxidant and antioxidant system
Production of ROS by neutrophil granulocytes in response to stimulation, the so-
called oxidative or respiratory burst, was measured in isolated neutrophils. Arterial 
blood was sampled at rest, Wmax and after 30 minutes of recovery in heparinized 
tubes. Cell isolation was performed by means of density centrifugation on Percoll 
immediately after sampling, as described previously.19 After isolation, cells were 
resuspended to a fi nal concentration of 2 x 106 cells·ml-1 and kept at room temperature. 
Luminol-enhanced chemiluminescence was measured in 96-well microplates at 37oC 
for 120 min in an automated LB96V Microlumat Plus luminometer (EG&G Berthold, 
Bad Wildberg, Germany). Per well 20 μl Luminol (10-4 M) was added to 100 μl of 
neutrophil suspension (2 x 106 cells·ml-1) that was either unstimulated or stimulated 
with 20 μl phorbol myristate acetate (5 μg·ml-1). Luminescence Peakheight, as a 
measure for maximum oxygen radical production was expressed in relative light 
units per second (RLU·sec-1). 
Total antioxidant capacity was assayed spectrophotometrically by measuring the 
ferric reducing ability of plasma.20 Blood samples were taken at rest, immediately 
after exercise and after 30 minutes of recovery in pre-cooled EDTA-containing tubes. 
The samples were centrifuged (1000g, 10 min) immediately after sampling and stored 
at –80oC until analysis. Concentrations of thiobarbituric acid reactive substances 
(TBARs), as marker for lipid peroxidation, were determined fl uorometrically.21 
Levels of protein carbonyls, a marker of protein oxidation, were measured by means 
of an ELISA.22 Samples for both protein and lipid oxidation were obtained at rest, 
immediately after exercise, and after 30 minutes of recovery in EDTA-containing 
tubes, and put on ice. After centrifugation (1000g, 10 min), supernatant was stored at 
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–80oC until analysis. Detection limits for carbonyls and TBARs were 0.065 nM and 
0.125 μM, respectively. All samples contained protein and lipid oxidation products 
above these limits.
Glutathione was measured in its reduced (GSH)23 and oxidized (GSSG)5 form. The 
oxidized-to-reduced ratio (%) of glutathione (GSSG/GSH), another frequently used 
marker of oxidative stress, was calculated.
Statistics
Between-group differences of baseline values and subjects’ characteristics were 
determined with Kruskal Wallis H. Repeated measures analysis of variance (ANOVA) 
was used to analyze all responses to exercise, with effects of time, group and the 
interaction between the two. Differences in the exercise-induced response patterns 
were tested using the interaction between each polynomial and the between-subject 
factors (time*group effect). Single degree of freedom orthogonal polynomials over 
time were used to characterize possible changes caused by exercise, i.e. linear and 
quadratic changes across time (time effect). These polynomials were examined 
for absolute values with all time points and for differences from baseline (for each 
subject). Comparisons between groups were only made (with Tukeys correction) if 
there was signifi cant heterogeneity across groups / over time. 
Linear regression analyses (Pearson’s correlation or Spearman rank test if normality 
was not assumed) were performed to test if FFMI, pulmonary function, systemic 
infl ammation, oxidative stress, and responses to exercise were correlated. Differences 
between the responses to maximal and submaximal exercise were evaluated with 
paired t-tests or Wilcoxon signed rank tests if normality was not assumed. Statistical 
signifi cance was taken at the p<0.05 level. Results are presented as means ± SE. 
Sizes of effect are presented as mean difference and its 95% confi dence interval 
(95% CI) Data were analyzed with SPSS/PC+, version 12.0 (SPSS, Chicago, IL).
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Results
Subjects
The characteristics of all participants are provided in Table 1. 
Data are expressed as means ± SE. 
Abbreviations: BMI, body mass index; FFMI, fat free mass index; FEV1, forced expiratory volume 
in fi rst second; VC, vital capacity; FRC, functional residual capacity; TLC, total lung capacity; KCO, 
diffusion capacity for carbon monoxide per unit of alveolar volume; PaO2, arterial oxygen tension; PaCO2, 
arterial carbon dioxide tension;  Pemax, maximal expiratory pressure of the respiratory muscles; Pimax, 
maximal inspiratory pressure of the respiratory muscles; MVCquadriceps, maximal voluntary contraction 
of the quadriceps muscle; pred, predicted value.
* p<0.05, ** p<0.01, *** p<0.001 versus healthy subjects
# p<0.05, ## p<0.01, ### p<0.001 versus non-muscle-wasted COPD patients
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According to the Global Initiative for Chronic Obstructive Lung Diseases (GOLD)24, 
the COPD groups showed mild (GOLD I: FEV1/VC <70%, and FEV1>80% predicted) 
to very severe (GOLD IV: FEV1/VC <70%, and FEV1<30% predicted) airfl ow 
obstruction and signs of hyperinfl ation. Muscle-wasted patients showed signifi cant 
loss of both respiratory (Pemax<80% predicted, p<0.05) and peripheral (quadriceps) 
muscle strength (MVCquadriceps, 171 N vs. 393 N in healthy subjects (p<0.01) and 
346 N in non-muscle-wasted patients(p<0.05)). In addition, FFMI and quadriceps 
strength were strongly correlated within COPD patients (r = 0.77, p<0.01).
Systemic infl ammation and oxidative stress at rest
Between-group differences were observed for basal systemic infl ammation 
and oxidative stress (Table 2). Baseline systemic infl ammatory mediators were 
signifi cantly higher in both muscle-wasted and non-muscle-wasted COPD patients 
vs. healthy subjects. Baseline infl ammatory values did not reach signifi cance between 
muscle-wasted and non-muscle-wasted patients. Oxidant production at rest did not 
differ between the groups, while antioxidant capacity was signifi cantly decreased in 
the muscle-wasted patients, as was refl ected by signifi cantly lower total antioxidant 
capacity (p<0.05 vs. both healthy subjects and non-muscle-wasted patients) and 
reduced GSH levels (p<0.05 vs. healthy subjects and p<0.01 vs. non-muscle-wasted 
patients). The imbalance between oxidants and antioxidants in muscle-wasted 
COPD patients resulted in signifi cantly increased protein oxidation (p<0.001) and 
a tendency towards increased lipid peroxidation (p=0.06) and GSSG/GSH ratio 
(p=0.07) compared with the non-muscle-wasted COPD group (Table 2). In addition, 
basal plasma antioxidant capacity, GSH, GSSG, GSSG/GSH, and IL-8 levels were 
related with muscle wasting (FFMI) and quadriceps strength (MVC) in patients with 
COPD (for correlation coeffi cients, see Table 3). Oxidant production at rest did not 
differ between the groups, while antioxidant capacity was signifi cantly decreased in 
the muscle-wasted patients, as was refl ected by signifi cantly lower total antioxidant 
capacity and reduced GSH levels. The imbalance between oxidants and antioxidants 
in muscle-wasted COPD patients resulted in signifi cantly increased protein oxidation 
and a tendency towards increased lipid peroxidation (p=0.06) and GSSG/GSH ratio 
(p=0.07) in especially this group (Table 2). In addition, basal oxidative status was 
related to muscle wasting and dysfunction in patients with COPD. Total antioxidant 
capacity and GSH were both positively correlated with FFMI (r =0.67, p<0.05, and 
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r =0.67, p<0.05, respectively), and peripheral muscle strength (r =0.80, p<0.001, 
and r =0.75, p<0.01). Furthermore, high GSSG levels were associated with low 
peripheral muscle strength (r = -0.73, p<0.05), and the highest GSSG/GSH ratios 
were found in COPD patients with the most muscle wasting (r= -0.43, p<0.05). 
Data are expressed as means ± SE.
Abbreviations: CRP, C-reactive protein; IL, interleukin; ra, receptor antagonist; TNF-α, tumour necrosis 
factor alpha; ROS, reactive oxygen species; RLU, relative light units; GSH, reduced glutathione; GSSG, 
oxidized glutathione; TBARs, thiobarbituric acid reactive substances.
* p<0.05, ** p<0.01, *** p<0.001 versus healthy subjects
§ p=0.05, # p<0.05, ## p<0.01, ### p<0.001versus non-muscle-wasted COPD patients     
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Abbreviations:  IL, interleukin; GSH, reduced glutathione; GSSG, oxidized 
glutathione; FFMI, fat free mass index; MVC, maximal voluntary contraction
* p<0.05, ** p<0.01, *** p<0.001
Physiological responses to exercise
Physiological responses to both maximal and submaximal exercise are shown in 
Table 4. As expected, exercise tolerance was limited in COPD patients. Within 
COPD patients, a positive correlation was found between FFMI and peak O2 
(r = 0.58, p<0.01). No difference in power output per kilogram muscle (W/kg fat free 
mass) was found between muscle-wasted and non-muscle-wasted patients. The main 
reason for stopping the maximal exercise was reported to be dyspnea in all COPD 
patients, and fi ve of them (all muscle-wasted patients) had also leg muscle pain. In 
contrast, healthy subjects complained of general fatigue on stopping exercise. 
The submaximal exercise at 50% of Wmax corresponded with a steady state O2 of 
~70% of the peak O2 reached during the maximal exercise in all groups (healthy 
subjects, 70 ± 3%; non-muscle-wasted COPD patients, 74 ± 2%; muscle-wasted 
COPD patients, 72 ± 3%). The lower intensity of the submaximal exercise was also 
refl ected by the smaller changes in lactate levels. Except for two COPD patients, all 
subjects maintained 30 minutes of cycling at 50% of Wmax. One muscle-wasted 
patient stopped cycling after 18 minutes because of breathlessness, and one non-
muscle-wasted patient only reached 20 minutes of cycling because of general 
fatigue.
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Data are expressed as means ± SE. 
Abbreviations: Endurance, duration of exercise test; HR, heart rate;  O2, oxygen consumption; 
 E, minute ventilation; MVV, maximal voluntary ventilation; ∆lactate, [lactate] post-exercise minus 
[lactate] pre-exercise.
(a)Peak HR and  O2 after maximal exercise, steady state HR and O2 during submaximal exercise.
* p<0.05, ** p<0.01, ***, p<0.001 versus healthy subjects
† p<0.05, ††p<0.01, †††, p<0.001 submaximal versus maximal exercise test
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Exercise-induced systemic infl ammation and oxidative stress
Exercise induced a signifi cant (time effect, p<0.001) leukocytosis in all groups 
(Figure 1). This leukocytosis had comparable patterns in all groups (time* group 
effect), but occurred at higher absolute levels in all COPD patients (group effect, 
p<0.05). In healthy subjects, the exercise-induced leukocytosis of the submaximal 
exercise was signifi cant diminished compared with the response to maximal exercise 
(maximal, from 6.0 ± 0.3 to 8.8 ± 0.5 ·109 cells⋅l-1; submaximal, from 5.5 ± 0.2 to 7.1 
± 0.2 ·109 cells⋅l-1, p<0.05). The response to submaximal exercise in COPD patients 
(both muscle-wasted and non-muscle-wasted), however, was not different from the 
response to maximal exercise.
Figure 1. Submaximal exercise-induced leukocytosis in healthy subjects, non-muscle-wasted and 
muscle-wasted COPD patients. Comparable responses (group*time effect) were observed in all groups, 
but absolute leukocyte numbers of all COPD patients (muscle-wasted and non-muscle-wasted) were 
signifi cantly higher compared to healthy subjects (group effects, * p<0.05 versus healthy subjects). 
Plasma IL-6 levels increased immediately after exercise in all groups (time effect, 
p<0.05). IL-6 changes (peak value – rest value) in response to maximal exercise 
were 0.7 pg⋅ml-1 (95% CI 0.17-0.90) in healthy subjects, 0.7 pg⋅ml-1 (95% CI 0.22-
1.0) in non-muscle-wasted patients , and 1.1 pg⋅ml-1 (95% CI 0.35-1.86) in muscle-
wasted patients, respectively. Post hoc analysis of these changes  revealed increased 
responses of IL-6 in the muscle-wasted group (p<0.05 versus both healthy subjects 
and non-muscle-wasted patients)(Figure 2). Comparing maximal to submaximal 
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exercise, the increase of IL-6 in healthy subjects was signifi cantly (p<0.05) lower 
after the submaximal exercise (change = 0.37 pg⋅ml-1, 95% CI 0.08-0.68). In 
contrast, maximal and submaximal exercises induced comparable increases of IL-6 
in non-muscle-wasted COPD patients. The increase of IL-6 in muscle-wasted COPD 
patients showed a tendency to be even higher after submaximal exercise compared to 
maximal exercise (p=0.07). Levels of CRP, IL-1ra, IL-8, and TNF-α were unchanged 
(time effect, p>0.05) by both exercise protocols in all groups.
Figure 2. Effect of exercise on plasma IL-6 levels in healthy subjects, non- muscle-wasted and muscle-
wasted COPD patients. Data are expressed as ∆IL-6  (peak value – rest value). IL-6 responses to 
exercise were signifi cantly higher in muscle-wasted COPD patients compared with non- muscle-
wasted patients and healthy subjects. In healthy subjects, the response to submaximal exercise was 
signifi cantly diminished compared to maximal exercise. In COPD patients, however, no differences 
between the exercises were observed. * p<0.05 versus healthy subjects; # p<0.05 versus non- muscle-
wasted patients; x p<0.05 versus maximal exercise.
Production of ROS in response to exercise was different between the groups 
(time*group effect, p<0.05). Neither maximal nor submaximal exercise induced 
changes of the oxidative burst of neutrophils in healthy subjects (change = 1.5%, 
95% CI –11 to 14). In non-muscle-wasted COPD patients, however, production of 
ROS increased in response to maximal exercise (+15%, CI 1-30), but not in response 
to submaximal exercise. The highest increase of ROS production (+32%, CI 8-54) 
was observed in muscle-wasted COPD patients (Figure 3), without differences 
between maximal and submaximal exercise.
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Figure 3. Oxidative burst of neutrophils before and after maximal exercise in healthy subjects, non- 
muscle-wasted and muscle-wasted COPD patients. Production of ROS in response to exercise was 
different between the groups (time*group effect, p<0.05). Neither maximal nor submaximal exercise 
induced changes of the oxidative burst of neutrophils in healthy subjects. In COPD patients, however, 
production of ROS increased in response to maximal exercise (+15%, CI 2-20%) and even further 
increased (+31%, CI 15-45%) in muscle-wasted COPD patients. 
Total antioxidant capacity in plasma decreased independent of exercise intensity. In 
all groups, both maximal and submaximal exercise caused a small but very consistent 
(time effect, p<0.05) decrease (-5%, 95% CI –6.5 to –1.5) of the antioxidant capacity 
(Figure 4). After 30 minutes of recovery, the antioxidant capacity rose to levels 
slightly above baseline (+8%, 95% CI 6-15) in all groups after both exercises. 
Overall, muscle-wasted COPD patients had lower antioxidant capacity compared 
with both healthy subjects and non-muscle-wasted COPD patients (group effects, 
p<0.05 versus healthy subjects; p<0.05 versus non-muscle-wasted patients).
Exercise was accompanied with increased lipid peroxidation in muscle-wasted 
COPD patients (change in TBARs = 0.32 μM, 95% CI 0.1-0.6), but not in the other 
groups (group effect, p<0.05 versus both healthy subjects and non-muscle-wasted 
patients) (Figure 5). No differences in the response to maximal and  submaximal 
exercises were seen. Also, there was a clear inverse relation between FFMI and the 
response of TBARs to exercise within the COPD patients (r = -0.59, p<0.01). 
Plasma carbonyl levels were not affected by exercise (time effect, p>0.05).
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Figure 4. Total antioxidant capacity of plasma before and after maximal exercise in healthy subjects, 
non- muscle-wasted and muscle-wasted COPD patients. In all groups, exercise induced a signifi cant 
decrease of the antioxidant capacity directly after exercise, followed by an increase above baseline 
values during 30 minutes of recovery (time*group effect, p>0.05; time effect, p<0.05). Overall, muscle-
wasted COPD patients had lower antioxidant capacity compared with both healthy subjects and non- 
muscle-wasted COPD patients (group effects, *  p<0.05 versus healthy subjects and versus non- muscle-
wasted patients).
Finally, exhaustive exercise caused glutathione oxidation in all groups. GSH levels 
signifi cantly and similarly decreased in all groups (change GSH = -200 μM, 95% CI –388 
to –55) (time effect, p<0.05; time*group effect, p>0.05, group effect, p>0.05)(Figure 
6A). Contrary to the decrease of GSH, GSSG levels increased after exercise (Figure 
6B). Immediately after exercise, the oxidation of glutathione increased in both COPD 
groups, but not in healthy subjects. During the 30 min of recovery, oxidation proceeded 
and increases up to 161% (95% CI 101-221), 173% (95% CI 70-279), and 232% (95% 
CI 164-300) of rest values were observed in healthy subjects, non-muscle-wasted and 
muscle-wasted COPD patients, respectively (group effects, p<0.05 muscle-wasted 
patients versus healthy subjects, and p<0.01 versus non-muscle-wasted patients). The 
exercise-induced changes in reduced and oxidized glutathione concentrations resulted 
in increased oxidative stress as is shown by highly increased GSSG-to-GSH ratios 
(Figure 6C). The ratio increased with similar patterns in the groups (time*group effect, 
p>0.05). However, signifi cantly more exercise-induced oxidative stress was seen in 
muscle-wasted patients (GSSG/GSG = 29%, 95% CI 22-36)(group effects, p<0.01 
versus healthy subjects; p<0.001 versus non-muscle-wasted COPD patients).
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Figure 5. Exercise-induced lipid peroxidation (TBARs) in healthy subjects, non- muscle-wasted and 
muscle-wasted COPD patients. TBARs were signifi cantly elevated after maximal exercise in muscle-
wasted COPD patients, but not in healthy subjects and non- muscle-wasted patients (group effects, 
*  p<0.05 versus healthy subjects, and versus non- muscle-wasted patients).
Discussion
Our results demonstrate that both maximal and submaximal exercise induce increased 
systemic infl ammatory and oxidative responses in muscle-wasted COPD patients, which 
are less pronounced or not seen in non-muscle-wasted patients and healthy subjects, 
respectively. These data support the concept of a role for systemic infl ammation and 
oxidative stress in muscle wasting of COPD patients. 
Low-grade basal systemic infl ammation and oxidative stress 
Different infl ammatory mediators that have been associated with increased resting 
metabolisms and weight loss 9;10, were elevated in COPD patients compared with healthy 
subjects and the highest levels of infl ammation (IL-8, IL-6, CRP) were seen in muscle-
wasted COPD patients (see Table 2). It has been suggested that increased levels of TNF-α, 
IL-1, and IL-8 may induce a catabolic response in tissues, triggering muscle proteolysis, 
with a resulting increase in protein degradation. Since negative feedback mechanisms 
(e.g. on TNF-α and IL-1) play an important role in the whole cytokine cascade, it remains 
diffi cult to identify the specifi c cytokines that may be involved in the catabolic response.
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Figure 6. Effect of maximal exercise on plasma levels of GSH (A),GSSG (B), and GSSG/GSH ratio (C) 
in healthy subjects, non- muscle-wasted and muscle-wasted COPD patients. GSH levels signifi cantly 
decreased in all groups in response to exercise (time effect, + p<0.05) while oxidized glutathione levels 
increased more in muscle-wasted COPD patients (group effects, # p<0.05 muscle-wasted patients 
versus healthy subjects, and ** p<0.01 versus non-muscle-wasted patients). The exercise-induced 
changes in reduced and oxidized glutathione concentrations resulted in increased oxidative stress as is 
shown by highly increased GSSG-to-GSH ratios. The ratio increased with similar patterns in the groups 
(group*time effect, p>0.05). However, signifi cantly more exercise-induced oxidative stress was seen 
in muscle-wasted patients (group effects, ## p<0.01 versus healthy subjects; *** p<0.001 versus non- 
muscle-wasted COPD patients).
To our knowledge, this is the fi rst study showing evidence that muscle wasting in 
COPD patients is not only accompanied with basal infl ammation, but also with less 
antioxidant capacity and a higher degree of oxidative stress at rest. Total antioxidant 
capacity and the level of the ubiquitous antioxidant GSH were signifi cantly reduced 
in muscle-wasted patients, and may have disturbed the oxidant/antioxidant balance, 
resulting in oxidative stress (lipid peroxidation and protein oxidation). The lack of 
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increased basal GSSG levels suggests an impaired synthesis of antioxidants rather 
than an increased oxidation in these patients. Contrary to previous studies 25;26, the 
release of ROS by neutrophils at rest was not increased in COPD patients. Since 
the sensitivity of ROS detection is dependent on the method used, this has probably 
contributed to the contrasting results. 
Correlations were found between muscle wasting, muscle dysfunction and different 
parameters of systemic infl ammation, and oxidative/antioxidative status (Table 3), 
indicating a possible causative effect of systemic infl ammation or oxidative stress on 
muscle wasting and function or vice versa. For now, we cannot distinguish between 
cause and direct consequence. 
Exercise-induced systemic infl ammatory and oxidative response
Previously, striking parallels have been observed between exercise and its complex 
regulatory and counter-regulatory responses in diseases states. Exercise induces 
changes in circulating leukocyte counts 2 that directly refl ect the changes in blood 
concentrations of (nor)epinephrine and cortisol, which are linearly related to the 
intensity of exercise. According to this theory, the present study indeed showed 
that the immediate leukocytosis in healthy subjects is lower after submaximal than 
after maximal exercise. Contrary, the exercise-induced leukocytosis in patients with 
COPD seemed to be independent of intensity. Because we showed recently that the 
(nor)epinephrine response to exercise in COPD patients was not different from the 
response in healthy subjects 7, this can not explain the discrepancies between the 
groups. 
The relation between intense exercise and circulating infl ammatory cytokines is well 
established. In the current study, both maximal and submaximal exercise resulted 
in signifi cant IL-6 responses (see Figure 2). Remarkably, the increases in muscle-
wasted COPD patients exceeded the responses of the other two groups. In COPD 
patients, the responses were similar after both maximal and submaximal exercise. 
These results strongly suggest that even moderate exercise further intensifi es the 
ongoing low-grade systemic infl ammation in patients with COPD, and may be 
involved in worsening extra-pulmonary effects like muscle damage. Rabinovich 
et al.6 also studied the cytokine response to moderate intensity exercise (11 min, 
40% Wmax) in healthy subjects and COPD patients with normal BMI (FFMI not 
reported). They found an abnormal exercise-induced increase of TNF-α in COPD 
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patients, but did not observe changes of IL-6 in COPD patients or healthy subjects. 
Absence of an increase in IL-6 in the latter group seems at least remarkable since 
appearance of this cytokine in the circulation after exercise is by far the most marked 
and its appearance precedes that of other cytokines.27 Maybe the differences in work 
intensities and duration between the two studies play a role in this discrepancy. Also, 
evaluation of different time points during exercise might give more insight in the 
time that is needed to see exercise-induced increases in systemic infl ammation.
Other studies have shown that physical exercise can induce systemic or local (e.g. 
in muscle) oxidative stress in patients with COPD.3;4 When the formation of free 
radicals exceeds the antioxidant capacity, the radicals can oxidize lipids, proteins, 
sugars, and other cell components, and thereby alter normal processes within 
cells and tissues. The present study showed that both maximal and submaximal 
exercise cause a signifi cant increase of free radical production in muscle-wasted 
COPD patients, while antioxidant capacity is decreased. This disbalance might have 
resulted in the observed lipid peroxidation. Priming of neutrophils is indicated by an 
augmented response of these cells produce reactive oxygen species without direct 
stimulatory actions upon the cells themselves. In response to cell stimulation, these 
primed cells can become activated to release reactive oxygen species and lysosomal 
enzymes, which in turn destroy cells and tissues. Cytokines are able to cause priming 
of neutrophils.28 According to this theory, the increased IL-6 response to cycling in 
muscle-wasted COPD patients might have been the primer for the neutrophils to 
produce more ROS. On the other hand, ROS are also known to induce production of 
infl ammatory mediators like IL-6.29 In that case, ROS can also have been the cause 
rather than the effect of the acute infl ammatory response to exercise.
Beyond the association between oxidative stress, muscle dysfunction and physical 
performance in COPD, the present data implicate that especially muscle-wasted 
patients may be frequently exposed to oxidative stress and the resulting tissue damage 
during daily life activities, which contain low-to-moderate intensity exercises. 
Clinical implications
Our results showed that systemic infl ammation and oxidative stress coexist in 
especially muscle-wasted COPD patients, and that these processes are further 
increased in response to relatively less exercise. The clinical implications of these 
fi ndings are not yet clear. In general, moderate exercise training is associated with 
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good or improved states of health, suggesting that factors like IL-6 and oxidants may 
play a role in the healthy adaptation to exercise. However, even in healthy subjects it 
is known that the very same process of exercise, if suffi ciently intense, can stimulate 
infl ammatory cytokines and lead to a catabolic state.30 Our fi nding that relatively less 
exercise in especially muscle-wasted COPD patients can additionally increase already 
elevated circulating levels of these mediators suggests that these patients might 
frequently be exposed to bursts of the chronic infl ammatory- and oxidative-catabolic 
responses during activities of daily life, holding them in a continuous catabolic state 
which may keep them in a vicious cycle of progression of the disease. Our study only 
investigated the systemic effects of acute exercise in stable patients with COPD, not 
including possible effects (e.g. adaptation) of chronic exercise. The investigation of 
Rabinovich and coworkers 6 has shown that 8 weeks of training could not modify 
the abnormal systemic infl ammatory response in patients with COPD. Theoretically, 
the benefi cial effects of exercise training in these patients, e.g. increase of physical 
performance, skeletal muscle mass and function, may be neutralized by the increased 
infl ammatory and oxidative responses to exercise. On the other hand, Mercken et al.31 
reported very recently that 8 weeks of pulmonary rehabilitation was associated with 
reduced exercise-induced oxidative stress in patients with COPD, suggesting that 
the body adapts to chronic exercise. Further studies are needed to evaluate possible 
adaptation mechanisms to decline the exercise-induced infl ammation and oxidative 
stress in patients with COPD. 
In view of both the resting catabolic state and possible infl uence on the effect of 
exercise training, it would be of interest to know if any intervention can modify the 
basal or exercise-induced systemic infl ammation and/or oxidative stress. Previously, 
it has been shown that exercise-induced oxidative stress can be (partially) prevented 
by antioxidants.3 In addition, Vassikopoulos et al.29 found a blunted cytokine response 
in healthy subjects after antioxidant therapy. Recently, however, it has also been 
shown that antioxidants did not prevent muscle damage in response to exhaustive 
exercise in healthy subjects.32 Effects of other therapies are under investigation now. 
Our own group has recently shown that exercise-induced oxidative stress in a group 
of muscle-wasted COPD patients could be prevented by supplemental oxygen.33 
Although clinical benefi ts of this prevention need to be elucidated, yet, these fi ndings 
invites further research in this area. 
Finally, our data implicate that special attention is needed for the group of muscle-
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wasting COPD patients. We think it would be a major clinical advancement if we were 
able to predict who will be a muscle waster and who will not. Early identifi cation of 
potential muscle wasting allows for more intensive therapy and possible mitigation 
of the disease.
In conclusion, the present study shows that exercise-induced systemic infl ammatory 
and oxidative response are increased in response to both maximal and submaximal 
exercise in muscle-wasted COPD patients compared to non muscle-wasted patients 
and healthy subjects. These fi ndings support the concept of an association between 
infl ammation, oxidative stress and muscle wasting or dysfunction. Frequent exposure 
to elevated levels of infl ammation and oxidative stress might hold muscle-wasted 
patients in a continuous catabolic state, keeping them in a vicious cycle of progression 
of the disease. Further studies are needed to evaluate 1) the exact mechanisms and 
direct consequences of systemic infl ammation and oxidative stress in COPD; 2) 
if daily life activities and/or training also intensifi es systemic infl ammation and 
oxidative stress; 3) whether or not muscle wasting in COPD can be prevented by 
diminishing systemic infl ammation and oxidative stress.
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Abstract
Systemic infl ammation and oxidative stress are potential mechanisms for muscle 
wasting in chronic obstructive pulmonary disease (COPD). The six-minute walking 
test (6MWT) has been suggested as simple and valid exercise test in COPD, which 
is well tolerated, and refl ective of activities of daily living. The present study 
investigated physiologic and systemic immunologic responses to a 6MWT in muscle-
wasted COPD patients and compared them with maximal cardiopulmonary exercise 
testing (CPET). 
10 muscle-wasted COPD patients were included (Fat Free Mass Index, FFMI; males 
<16 kg·m-2, females <15kg·m-2). A 6MWT and CPET were carried out in random 
order. The physiologic response was followed by a mobile oxycon. Arterial blood was 
obtained at rest and after exercise to measure blood gases and markers of systemic 
infl ammation and oxidative stress.
In these patients (FEV1 55 ± 4 % pred), the 6MWT was a submaximal, albeit intense, 
exercise as refl ected by O2, E, heart rate, and lactate values. Leukocytosis was 
less intense after 6MWT compared to CPET. Contrary, the increase in IL-6, free 
radical release by neutrophils, oxidation of proteins and lipids, and the reduction in 
antioxidant capacity were similar after both exercises. FFMI was inversely related to 
6MWT-induced increases in protein and lipid peroxidation. 
This study shows that a 6MWT induces a systemic immunologic response in 
muscle-wasted COPD patients, which is comparable to CPET-induced responses. 
The correlation between systemic oxidative stress and the degree of muscle wasting 
supports a possible causal relation between systemic infl ammation, oxidative stress 
and muscle wasting.
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Introduction
Chronic obstructive pulmonary disease (COPD) is defi ned currently by the ATS/
ERS as a disease characterized by airfl ow limitation, which is not fully reversible 
and produces signifi cant systemic consequences.1 This systemic involvement in 
COPD has become extremely important since it seems conceivable that exploring 
the presence of systemic biomarkers and their relation to systemic manifestation of 
the disease, will help us in developing and applying novel strategies that will improve 
outcome of our patients. Based on the current understanding of the pathobiology 
of COPD, most notably suggested markers are the infl ammatory cells and their 
products that are believed to be the proximate causes of tissue destruction in patients 
with COPD.2 The exact meaning of these biomarkers are not elucidated yet, and 
may be multifactorial, but both systemic infl ammation and oxidative stress have 
been associated with loss of muscle mass and muscle dysfunction.3-6 Very recently, 
moderate and high intensity cycle ergometry has shown to increase systemic 
infl ammation and oxidative stress 7, especially in the subgroup of muscle-wasted 
COPD patients.5 Although strong evidence is lacking, frequent exposure to these 
effects might play a role in the ongoing muscle wasting and its consequences in these 
patients. Additionally, it was shown that cycling-induced systemic infl ammation in 
these muscle-wasted patients could be attenuated and oxidative stress be prevented 
by supplemental oxygen during exercise.8 Based on these results, we postulated that 
daily life activities, which can be classifi ed as moderate intense for these patients, 
can cause frequent bursts of systemic infl ammation and oxidative stress which may 
be involved in muscle wasting. Patients with COPD, however, are relatively inactive 
and they will not perform cycle exercises regularly. The six-minute walking test 
(6MWT) has been suggested as a simple and valid exercise test in COPD, which is 
well tolerated, and refl ective of activities of daily living.9 The physiologic responses 
to 6MWT in patients with COPD has been studied previously  and described as 
maximal 10 or submaximal 11 sustainable exercise in these patients. 
The current study was designed to characterize both the physiologic and systemic 
immunologic responses to a 6MWT in muscle-wasted COPD patients and compare 
them with the responses to maximal cardiopulmonary exercises testing (CPET). 
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Methods
Subjects
Ten (6 males) ex-smoking, muscle-wasted COPD patients (Fat Free Mass Index, 
FFMI; males <16 kg·m-2, females <15kg·m-2)12 participated in this study. The 
patients were recruited from our outpatient clinic and had moderate to severe COPD 
according to the GOLD classifi cation.1 All had been free of exacerbations for at 
least two months prior to the study, and had stopped smoking at least 6 months 
before inclusion. Exclusion criteria were the use of oral corticosteroids, long-term 
oxygen therapy, and other chronic infl ammatory or exercise-limiting diseases. The 
use of inhaled corticosteroids (n=6) and antioxidants (N-acetylcysteine, n=3) was 
discontinued one week prior to exercise testing. All patients were on bronchodilator 
therapy, none used theophylline. The study was conducted according to the 
Declaration of Helsinki and was approved by the medical ethical committee of our 
hospital. Written informed consent was obtained from all subjects.
Study design
As part of the characterization procedures, resting pulmonary function, bioelectrical 
impedance analysis (Biostat 1500, Bodystat LTD, Douglas, Isle of Man, British 
Isles), and peripheral muscle strength (as described in 5) were carried out in all 
patients. Weight parameters were adjusted for body surface to give body mass 
index (BMI) and FFMI. On two different study days (separated by one week), two 
exercise protocols were carried out in random order: 6MWT and CPET. During both 
exercises, the physiologic response was followed in all participants. In all patients 
arterial blood was obtained from a catheter in the radial artery to measure blood 
gases, lactate concentrations and systemic infl ammation and oxidative stress at rest 
and in response to the exercises. 
Exercise testing
A portable breath-by-breath system (Mijnhardt/Jaeger, Bunnik, The Netherlands) a 
pulse-oxymeter (Datex, Helsinki, Finland), and a polar belt were used to monitor 
oxygen consumption ( O2), carbon dioxide production ( CO2), respiratory exchange 
ratio (RER), minute ventilation ( E)¸ and heart rate (HR) on-line during exercise. 
Validation of this new system, the mobile oxycon, is described in the equipment 
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section below. Before exercise, a catheter was inserted into the radial artery to obtain 
arterial blood before, during and  directly after (within 15 sec) exercise.
The 6MWT was performed according to the ATS guidelines.13 All patients were 
familiar with the test. A straight walking course of 30m was used and two cones 
marked the turnaround points. Before the 6MWT, the patient sat in a chair for at least 
30 minutes to measure stable physiologic and immunologic baseline values. After 
starting the exercise, participants were encouraged every minute with standardized 
phrases. Patients were allowed to stop and rest during the six minutes of exercise, but 
none of the participants in this study stopped walking before fi nishing the complete 
6 minutes.
A maximal, symptom limited, incremental bicycle test was carried out on an electrical 
braked cycle ergometer (Masterlab®, Jaeger, Würzburg, Germany) according to the 
ATS guidelines.14 
Equipment
Using the mobile oxycon and the belonging software, we were able to evaluate the 
physiological response to the 6MWT with the 9-panel plots.15 The portable system 
consisted of a face mask, polar belt, battery and transmitting unit (containing the 
O2 and CO2 gas analyzers), and a receiving unit. The transmitting unit with battery 
pack and face mask with tubing (total weight 0.5 kg) was attached to the individual 
with a harness, and the receiving unit was connected to a personal computer 
anywhere within 500 m of the transmitting unit. The face mask contained a turbine 
for measurement of ventilation as well as a capillary gas sampling port within the 
turbine’s housing. The expired gas was sampled at a rate proportional to ventilation 
into a microchamber containing O2 and CO 2 electrodes. O2 and CO2 analyzers were 
thermostated and compensated for the variations of barometric pressure and humidity 
of the environment. Calibration of the turbine by use of a 3-liter syringe and a two-
point calibration of the gas analyzers by use of gas mixtures from tanks of standard 
gas were performed before each test.
Before the study, the agreement between the mobile oxycon and the breath-by-breath 
(Oxyconbeta, Mijnhardt/Jaeger, Bunnik, The Netherlands) systems in assessing 
pulmonary physiological parameters was verifi ed in four healthy subjects at different 
exercise levels of cycle-ergometer exercise: 1) incremental test until exhaustion, and 
2) moderate constant work rate tests at 25% and 75% of maximal workload (Wmax) 
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achieved during test 1. Subjects performed each protocol on both the mobile oxycon 
and breath-by-breath systems. The test order was randomized. Values of O2, CO2, 
and E did not differ signifi cantly between mobile oxycon and breath-by-breath, 
either at peak or at submaximal level of exercise. With the Bland-Altman test 16, the 
mean O2 difference between the two methods was 10.1 ml⋅min-1, and the limits of 
agreement (means ± 2 SD) were + 171.8  to –151.7 ml⋅min-1. The biases in  CO2 
and E were comparably small. Furthermore, two walking tests of 5 minutes on a 
treadmill (5 km/h) were performed with the mobile oxycon. In this way an intratest 
variability of <11% was measured.
Analysis
Arterial blood gases (oxygen tension, PaO2; carbon dioxide tension, PaCO2) and lactate 
levels were determined immediately after sampling (Gas analyzer Chiron 860). 
Plasma cytokines were before and after the exercises using quantitative sensitivity 
and high-sensitivity sandwich enzyme-linked immunosorbent assays (ELISA’s) in 
kit form (R&D systems, Minneapolis, USA) according to the supplier’s instructions. 
Leukocyte counts and CRP were determined at rest and  immediately after exercise, 
following standard laboratory assays. 
Production of reactive oxygen species (ROS) by neutrophil granulocytes in response 
to stimulation with phorbol myristate acetate (PMA), the so-called oxidative burst, 
was measured in isolated neutrophils. Cell isolation was performed by means 
of density centrifugation on Percoll immediately after sampling, as described 
previously.17 Luminol-enhanced chemiluminescence was measured with an 
automated LB96V Microlumat Plus luminometer (EG&G Berthold, Bad Wildberg, 
Germany) as described by Wanten et al.18 Luminescence Peakheight, as a measure for 
maximum oxygen radical production was expressed in relative light units per second 
(RLU/sec). Exercise-induced changes in luminescence were expressed relatively to 
luminescence values obtained at rest. 
Total antioxidant capacity was assayed spectrophotometrically by measuring the 
ferric reducing ability of plasma, as described by Benzie et al.19 
Concentrations of thiobarbituric acid reactive substances (TBARs), as marker for 
lipid peroxidation, were determined fl uorometrically using the method described 
by Conti et al.20 Levels of protein carbonyls, a marker of protein oxidation, were 
measured by means of an ELISA as described by Buss et al.21, and modifi ed by 
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Zusterzeel et al.22 
Measurements after exercise were corrected for plasma volume shifts according to 
Dill and Costill.23 
Statistical analyses
Group data are expressed as mean values ± SE. Comparisons between rest and 
exercise values were made using Student paired t tests (or Wilcoxon signed-rank 
test if normal distribution was not assumed). When the response to exercise was 
expressed as percentage change compared to baseline, a one sample t test (or 
Mann Whitney U test) was used. Comparisons between 6MWT and CPET were 
made using Student paired t tests (or Wilcoxon signed-rank test). One way analyses 
of variance (ANOVA) for repeated measurements were carried out to examine 
physiologic profi les at the different exercise protocols. Spearman Rank tests were 
used to evaluate the correlations between physiological response, immune response, 
and muscle wasting. The level of statistical signifi cance was set at p<0.05. 
Results
The study group (Table 1) showed moderate-to-severe airfl ow obstruction (FEV1, 
1.55 ± 0.20 L; 55 ± 4 % predicted, range 36 to 74 % predicted) without arterial 
hypoxemia or hypercapnia at rest. Mean FFMI was 14.1 kg·m-2 in females and 14.8 
kg·m-2 in males. 
Physiologic responses
Figure 1 displays O2 and E profi les during 6MWT and CPET in the same patients. 
Both O2 and E  showed a steady-state profi le during the last 4 minutes of 6MWT, 
while they gradually increased until exhaustion during CPET. Comparing O2 and 
E after 6 min of walking and cycling (isotime), no signifi cant differences were seen. 
In contrast, peak O2 and E were signifi cantly higher (both p<0.01) than steady state 
6MWT (6th min) values. Also, heart rate and lactate values were signifi cantly lower 
after 6MWT compared with CPET (p<0.01 and p<0.001, respectively). Detailed 
information on physiological responses is provided in Table 2. 
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Values are represented as mean ± SE
Abbreviations: BMI, body mass index; FFMI, fat free mass index; FEV1, forced expiratory volume in 
fi rst second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; FRC, functional 
residual capacity; KCO, diffusion capacity for carbon monoxide per unit of alveolar volume; PaO2, 
arterial oxygen tension; PaCO2, arterial carbon dioxide tension; Pi max, maximal inspiratory mouth 
pressure; Pe max, maximal expiratory mouth pressure, MVCquadriceps, maximal voluntary contraction of 
the quadriceps muscle; pred, predicted value.
Figure 1. Physiologic responses during exercise. Mean data ± SE for oxygen uptake ( O2) (A), and 
minute ventilation ( E) (B) during CPET and 6MWT.
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Values are represented as mean ± SE. 
Abbreviations: 6MWD, 6-minute walking distance;  O2, oxygen consumption;  CO2, carbon 
dioxide production; RER, respiratory exchange ratio;  E, minute ventilation; BR, breathing reserve; 
Bf, breathing frequency; HR, heart rate; PaO2, arterial O2 tension; PaCO2, arterial CO2  tension; P(A-a)O2, 
alveolar-arterial PO2 pressure difference; VD, physiologic dead space; VT, tidal volume; pred, predicted 
value. 
†  E/ CO2 during CPET at anaerobic threshold, during 6MWT at 6th min of walking (lack of anaerobic 
threshold). 
* p<0.05, ** p< 0.01, *** p<0.001 6MWT versus CPET.
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Immunologic responses
A signifi cant leukocytosis occurred after both CPET (p<0.001) and 6MWT (p<0.01), 
which was caused by increases in all subsets. Compared to the response to CPET, 
the increase of the circulating infl ammatory cells was less intense after the 6MWT 
(Figure 2), with signifi cantly lower changes in total leukocytes (CPET, +20%; 
6MWT,+10%, p<0.05) and lymphocytes (CPET, +38%; 6MWT,+17%, p<0.01). 
Plasma levels of IL-6 were signifi cantly increased after CPET (from 5.62 ± 1.1 
pg⋅ml-1 to 6.33 ± 1.4 pg⋅ml-1, p<0.05). and 6MWT (from 5.95 ± 1.3 pg⋅ml-1 to 6.77 
± 1.5 pg⋅ml-1, p<0.05), as shown in Figure 3. The mean increase after walking was 
not different from the response to CPET (0.82 ± 0.3 pg⋅ml-1 versus 1.0 ± 0.4 pg⋅ml-1, 
p>0.05).
Figure 2. Leukocytosis to exercise. Comparison of increases in leukocytes and subsets after CPET and 
6MWT. * p<0.05, ** p<0.01 6MWT versus CPET; ns, not signifi cant.
Figure 3. IL-6 response to exercise. Both CPET and 6MWT induced a signifi cant increase of IL-6 
levels compared to rest values. The IL-6 response was comparable between the two different exercises. 
# p<0.05 versus rest.
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Exercise induced free radical production by neutrophils (Figure 4A). Isolated 
neutrophils produced signifi cantly more ROS after walking than at rest (change = 28 
± 8% in stimulated cells, p<0.01). Comparable changes in neutrophil ROS production 
were observed after CPET (change = 29 ± 11%, p<0.01). While the production of 
oxidants increased, plasma antioxidant capacity signifi cantly decreased in response 
to exercise (Figure 4B). A relatively small but consistent decrease of ~8% after 
6MWT resembled the response to CPET.
Figure 4. Production of reactive oxygen species (ROS) by PMA-stimulated neutrophils (A), and plasma 
total antioxidant capacity (B) before and after CPET and 6MWT. Exercise-induced oxidative burst was 
comparable between cycling and walking. RLU/sec, relative light units per second (chemiluminescence). 
Antioxidant responses were not different between the two exercises. # p<0.05 versus rest, ## p<0.01 
versus rest.
As markers of free radical-induced tissue or cell damage, both plasma levels of 
carbonyls and TBARs were signifi cantly elevated after 6MWT (p<0.05 and p<0.01, 
respectively) (Figure 5). Also after CPET, levels of TBARs were increased (p<0.05), 
whereas carbonyls remained unchanged. 
Finally, the magnitude of the systemic oxidative stress response was related to the 
degree of muscle-wasting. Figure 6 shows that increases in both plasma carbonyls 
and TBARs were signifi cantly correlated to FFMI (r = 0.83, p<0.01, and r = 0.75, 
p<0.05, respectively). Contrary, systemic oxidative stress response was not correlated 
with BMI (p>0.05).
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Figure 5. Oxidative stress in response to CPET and 6MWT. Plasma levels of carbonyls (protein 
oxidation) (A) and TBARs (lipid peroxidation) (B) at rest and after CPET and 6MWT. # p<0.05, ## 
p<0.01 versus rest; ns, not signifi cant.
Figure 6. Relation between muscle-wasting and magnitude of exercise-induced oxidative stress. FFMI 
was inversely correlated with 6MWT-induced increases in both plasma carbonyls (r = 0.83, p<0.01) 
and TBARs (r = 0.75, p<0.05).
Discussion
The most important fi nding of the current study in muscle-wasted COPD patients is 
the increased systemic infl ammation and oxidative stress after a 6MWT. Both the 
IL-6 and oxidative response to 6MWT are comparable to CPET induced responses. 
Furthermore, the degree of muscle-wasting was correlated with the increase of 
oxidative stress. Physiologically, the 6MWT is a submaximal, albeit intense, exercise 
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in these patients, as refl ected by lower O2,  E and lactate values after walking 
compared to CPET. 
Physiologic response
A clear steady state O2 was shown in the last 4 minutes of the 6MWT as has also 
been described by others.10;11 Although the patterns of the physiologic response 
to both exercises were different, at isotime (6 minutes of exercise), ventilatory 
requirements (lower O2,  E ) were similar between walking and cycling. In 
contrast with fi ndings of Troosters et al.10, who found identical O2  and HR after 
6MWT and CPET, the physiological burden imposed on the system, in terms of 
both ventilatory and cardiovascular response, was lower after 6MWT than at peak 
cycling in the present study. Discrepancies between the two studies may be due 
to differences in patient characteristics. Our patients showed slightly higher FEV1, 
less hyperinfl ation, and more muscle wasting compared to the patients in the study 
by Troosters et al. Furthermore, 6MWD was considerably higher in the patients of 
Troosters et al, although maximal work rates during cycling were similar. 
In the present study O2 during 6MWT (3
rd-6th min) was lower compared with peak 
O2 after CPET. It is worth noting, however, that all patients were capable of walking 
for 4 minutes at >80% of their maximal O2. Half of these patients even fi nished 
their 6MWT without any breathing reserve. Together with the lower lactate levels 
after 6MWT compared to CPET, this study supports earlier work10 that suggests 
that the 6MWT generates high, albeit submaximal, metabolic and cardiovascular 
requirements.
Systemic immunologic response
Despite the fact that the leukocytosis of exercise 24 is affected by type, intensity and 
duration of the exercise, several consistent patterns emerge regarding the leukocyte 
subpopulations in blood. The current study showed that a 6MWT already induces a 
typical systemic leukocytosis, as a result of an increase in all leukocyte subpopulations. 
Immediately after start of muscular exercise, epinephrine and norepinephrine are 
released into the plasma. These stress hormones have marked physiological effects 
on heart rate and vasomotor tone, and ultimately on blood fl ow through lymphoid 
tissues and leukocyte circulation patterns.25 Catecholamines increase almost linearly 
with the duration of exercise and exponentially with intensity, when it is expressed 
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relative to individual’s peak O2.
26 In line with the observation that the 6MWT is 
another type of exercise, less intense and a little shorter than CPET, the leukocytosis 
was less pronounced after 6MWT. In contrast, the plasma IL-6 response to exercise 
was similar between 6MWT and CPET. IL-6 precedes the appearance of other 
infl ammatory mediators 27 and is related to fat-, protein- and muscle depletion.28 
Infl ammatory markers have indeed been found in skeletal muscles of patients with 
COPD.29 Whether IL-6 indeed plays a role in the ongoing and progressing systemic 
infl ammation and its consequences in COPD, needs to be elucidated further. 
Regarding the oxidative response, earlier results have shown that exercise in COPD 
leads to a disturbance of the oxidant/antioxidant balance, which may result in free 
radical mediated tissue damage.5;30-33 Following CPET and submaximal ergometry 
5;6, the current data showed that the oxidative burst of neutrophils increased, and total 
antioxidant capacity of plasma decreased after 6MWT, resulting in an increase of 
systemic oxidative stress. Although the 6MWT has been shown to be a submaximal, 
but relatively intense exercise for patients with COPD, it is also suggested to refl ect 
activities of daily life.9;34 Consequently, this would support our concept that patients 
with COPD are regularly exposed to bursts of oxidative stress. In this respect, 
additional research to the exposure to oxidative stress and infl ammation during daily 
activities is needed. Also, the question arises whether the described responses are 
specifi c for muscle-wasted COPD patients and thereby support the concept of possible 
negative consequences, like muscle wasting or damage. Previously, we showed that 
the systemic responses to high and moderate cycling indeed were specifi c for muscle-
wasted COPD patients and not seen in non-muscle wasted patients and healthy 
subjects.5 Our present fi nding that the degree of muscle wasting was correlated with 
the magnitude of the systemic oxidative response, further supports a possible causal 
relation between systemic infl ammation, oxidative stress and muscle wasting.
Some limitations of the present study and suggestions for future research deserves 
discussion. A relatively small number of patients was included in the study. The 
results, however, were very consistent within these 10 patients and thereby seem to 
be representative for these group of patients. Furthermore, muscle wasting is usually 
seen in GOLD stage 3 and 4 of the disease. Our study group had less severe COPD 
(GOLD  2 and 3). Diminished exercise capacity (maximal workload of 89W) and 
clear respiratory and peripheral muscle weakness, however, supported the wasted 
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condition in these moderate to severe COPD patients. 
Finally, attention should be paid to the clinical relevance of increased oxidative 
stress. Different mechanisms are known to be involved in the generation of free 
radicals, e.g. mitochondrial electron transport chain, activated neutrophils, ATP 
degradation, aldehyde oxidase, arachidonic acid cyclo-oxygenase pathway, and 
nitric oxide synthase. Free radical release from contracting skeletal muscles have 
been shown, but using in vivo models, it is impossible to exclude other sources, 
including liver, lung , small intestine, or circulating cells.  There is good evidence 
that overproduction of free radicals is associated with muscle dysfunction. On the 
other hand, it is also known that free radicals are needed for optimal muscle function. 
To fi nd out the clinical relevance of the oxidative burst, we support future research 
to markers of muscle damage and mechanistic studies to the source of oxidative 
stress and its consequences in these patients. Recently, it was shown that pulmonary 
rehabilitation was associated with reduced exercise-induced oxidative stress in 
COPD.33 On the other hand, patients with COPD showed a reduced ability to adapt 
to endurance training compared to healthy subjects, refl ected in lower capacity to 
synthesize the antioxidative GSH.35 This decreased glutathione synthesis may be of 
great concern in muscle-wasted COPD patients. Furthermore, supplemental oxygen 
has been show to attenuate exercise-induced free radical production by neutrophils 
and ATP degradation, resulting in the prevention of exercise-induced oxidative stress 
in muscle-wasted COPD patients.8 Additionally, supplemental oxygen seemed to 
interfere in one of the infl ammatory pathways, resulting in a decreased exercise-
induced IL-6 response. Understanding the mechanisms of the systemic disease 
COPD will help us understanding the disease and fi nally optimize the treatment 
strategies for these patients.
In conclusion, the present study has shown that a 6MWT induces a systemic 
immunologic response in muscle-wasted COPD patients, which is comparable to 
CPET induced responses. Since walking is regularly performed during daily life, it 
might be postulated that muscle-wasted patients with COPD are regularly exposed 
to bursts of systemic infl ammation and oxidative stress. The correlation between 
systemic oxidative stress and the degree of muscle wasting further supports a possible 
causal relation between systemic infl ammation, oxidative stress and muscle wasting. 
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Abstract
Although oxygen therapy is of clear benefi t in patients with severe chronic 
obstructive pulmonary disease (COPD), recent studies have shown that short-term 
supplementary oxygen may increase oxidative stress and infl ammation within the 
airways. We investigated whether systemic infl ammation and oxidative stress at rest 
and during exercise in patients with COPD are infl uenced by supplemental oxygen.
Nine normoxemic, muscle-wasted patients with moderate to very severe COPD were 
studied. Plasma markers of systemic infl ammation (leukocyte counts, interleukin 
6 (IL-6)) and oxidative stress (lipid peroxidation, protein oxidation, antioxidant 
capacity) were measured after treatment with either supplemental oxygen (nasal, 
4 L·min-1) or compressed air, both at rest (1 h treatment) and after submaximal exercise 
(40 W, constant work rate). In addition, free-radical production by neutrophils and 
ATP-degradation products were determined before and after exercise.
Short-term oxygen breathing at rest did not infl uence systemic low-grade infl ammation 
and oxidative stress. The IL-6 response to exercise was attenuated during cycling with 
supplemental oxygen. Exercise-induced lipid and protein oxidation were prevented 
by treatment with supplemental oxygen. This was associated with both decreased free-
radical production by neutrophils and reduced formation of (hypo)xanthine and uric 
acid. Short-term supplementary oxygen does not affect basal systemic infl ammation 
and oxidative stress but prevents exercise-induced oxidative stress in normoxemic, 
muscle-wasted patients with COPD, and attenuates plasma IL-6 response. Inhibition 
of neutrophil activation and ATP degradation appears to be involved in this effect.
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Introduction
Long-term oxygen therapy is one of the few treatments with clear benefi ts for 
hypoxemic patients with chronic obstructive pulmonary disease (COPD). It prolongs 
survival, reduces the frequency of hospitalization and development of pulmonary 
hypertension, and improves exercise performance and quality of life.1–3 Although 
benefi ts are less pronounced, supplemental oxygen has been shown to reduce 
ventilation, dynamic hyperinfl ation, and dyspnea during exercise in normoxemic 
patients with COPD and in those with mild hypoxemia and COPD.4;5
Despite the proven benefi ts of oxygen therapy in COPD, recently published data 
may shed another light on the effects of this therapy. Philips and coworkers 6 reported 
that breathing of 28% oxygen at 2.0 L·min-1 via nasal prongs for 30 min while resting 
resulted in an increase of breath methylated alkane contour in healthy subjects, 
suggesting increased oxidative stress in exhaled breath. In addition, Carpagnano 
and coworkers 7 investigated the effects of short-term supplementary oxygen on 
markers of oxidative stress and infl ammation in exhaled breath condensate in both 
healthy subjects and patients with COPD. Exposure to increased inspiratory oxygen 
fraction (FiO2, 0.28) for 1 h resulted in enhanced concentrations of interleukin 6 
(IL-6) and 8-isoprostane in exhaled breath condensate of patients with COPD and 
healthy subjects. It is unknown if supplemental oxygen as used in clinical practice 
alters systemic markers of oxidative stress and infl ammation. In healthy subjects, 
there is some evidence that markers of oxidative stress (i.e., lipid peroxidation and 
superoxide dismutase activity) in plasma are increased after hyperbaric oxygen 
therapy.8;9 Data on the effects of increasing FiO2 on these markers in patients with 
COPD are not known to the best of our knowledge.
Markers of oxidative stress and infl ammation are known to be increased by intense 
exercise in healthy subjects. Oxidative stress and infl ammation are now recognized to 
play an important role in the pathogenesis of COPD 10;11, and an increased response to 
exercise has also been described in patients with COPD.12;13 The effect of oxygen on 
exercise-induced systemic oxidative stress and infl ammation in patients with COPD 
is largely unknown. Vina and colleagues 14 showed in fi ve patients with very severe 
COPD (FEV1, 0.79 ± 0.07 L) with advanced hypoxemia (PaO2, 7.5 ± 0.1 kPa) that 
exercise-induced (constant work rate, 40 W) blood glutathione oxidation was partially 
reduced by supplemental oxygen (2–3 L·min-1), indicating that supplemental oxygen 
Chapter 6
116
decreased exercise-induced oxidative stress. Mechanistically, it is unknown which 
of the three major sources of intracellular free-radical generation (e.g., neutrophils, 
mitochondrial electron transport chain, and the xanthine oxidase pathway 12;15;16) are 
affected by supplemental oxygen.
We investigated the effect of short-term supplemental oxygen at rest and during 
exercise on markers of systemic infl ammation and oxidative stress in normoxemic 
patients with moderate to very severe COPD. In a crossover design, plasma markers 
of infl ammation (circulating leukocytes, concentration of IL-6) and oxidative stress 
(lipid peroxidation and oxidation of proteins) were measured in nine patients with 
COPD during treatment with either compressed air (nasal, 4 L·min-1) or supplemental 
oxygen (nasal, 4 L·min-1), both at rest (after 1 h treatment) and after a bout of cycle 
exercise (40 W, constant work rate). To improve insight in the possible mechanisms 
involved in these systemic effects, both ATP-degradation products 12;17 and neutrophil 
activation 15;16 were measured. In the present study, we selected muscle-wasted 
patients with COPD to evaluate the systemic effects of supplemental oxygen, because 
of the increasing evidence for a relation between systemic infl ammation, oxidative 
stress, and muscle wasting in COPD 11; 18; 19, and the importance of any intervention 
on these features in this specifi c subgroup of patients with COPD.
Methods
Subjects
Nine (fi ve males) muscle-wasted patients with COPD (fat-free mass index: males 
< 16 kg·m-2, females < 15 kg·m-2) 20 participated in this study. The patients were 
recruited from our outpatient clinic and had moderate to very severe COPD 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
classifi cation.21 All had been free of exacerbations for at least 2 mo before the study, 
and had stopped smoking at least 6 mo before inclusion. Exclusion criteria were 
the use of oral corticosteroids, long-term oxygen therapy, respiratory insuffi ciency 
(PaO2 < 8 kPa, PaCO2 > 6.7 kPa), and other chronic or exercise-limiting diseases. 
The use of inhaled corticosteroids (n = 4), antioxidants (n = 1), and supplemental 
vitamins was discontinued 1 wk before exercise testing. All patients were on 
bronchodilator therapy; none used theophylline. The study was conducted according 
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to the Declaration of Helsinki and was approved by the medical ethical committee of 
our hospital. Written, informed consent was obtained from all subjects.
Study Design
Pulmonary function, body composition, and a maximal, symptom-limited, 
incremental bicycle test were assessed as part of the characterization procedure. 
In two subsequent visits (separated by 1 wk), the systemic effects of supplemental 
oxygen were evaluated in a double-blind, randomized, and placebo-controlled 
crossover design (Figure 1). At rest, subjects breathed either supplemental oxygen 
or compressed air via nasal prongs for 1 h at a fl ow rate of 4 L·min-1. After a wash-
out period of 2 h breathing ambient air, a submaximal constant work rate bicycle test 
at 40 W was performed with either supplemental oxygen or compressed air (nasal, 
4 L·min-1, again randomized and double blind). Oxygen supplementation of 4 L·min-1 
was chosen because this fl ow rate is commonly used in training programs for patients 
with COPD.3; 22 A work rate of 40W was used to produce an energy expenditure 
of approximately 3 metabolic equivalents, which is equivalent to the power output 
required to walk in usual activities during daily life.23 Patients were instructed to 
cycle as long as possible but for a maximum of 30 min. One week later, the protocol 
was repeated with the other interventions (crossover). At this second visit, patients 
were instructed to cycle exactly as long as at the previous visit, if possible. Because 
of the nasal prongs for supplementation of oxygen or compressed air, we were not 
able to measure ventilatory parameters breath by breath during cycling. At both 
visits, fi ve arterial blood samples (20 ml/sample) were taken. Samples A1 and A2, 
and A4 and A5, were used to evaluate the effects of supplemental oxygen compared 
with compressed air at rest and during exercise, respectively. Sample A3 was used 
to control wash-out values with baseline values. Measurements after exercise 
were corrected for plasma volume shifts according to Dill and Costill.24 Changes 
in systemic infl ammation and oxidative stress in response to supplemental oxygen 
compared with compressed air were measured after 1 h at rest and after constant 
work rate bicycle exercise.
Blood Gas and Lactate Analysis
Arterial blood gasses (PaO2, PaCO2) and lactate concentrations were measured using 
Gas analyzer Chiron 860 (Bayer, Massachusetts, USA).
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Systemic Infl ammation
Plasma IL-6 concentrations were measured using quantitative sensitivity and 
high-sensitivity sandwich ELISAs in kit form (R&D Systems, Minneapolis, MN) 
according to the supplier’s instructions (detection limit, 0.039 pg·ml-1). Leukocyte 
counts were determined following standard laboratory assays.
Oxidative Stress
Concentrations of thiobarbituric acid–reactive substances (TBARs) were determined 
fl uorometrically.25 Levels of protein carbonyls were measured by means of an 
ELISA.26;27
To investigate the role of free-radical generation by neutrophils, production of reactive 
oxygen species by isolated neutrophils (stimulated with phorbol myristate acetate) 
was measured by chemiluminescence.28;29 To evaluate the role for ATP degradation, 
plasma levels of xanthine, hypoxanthine, and uric acid were measured by a standard 
HPLC method with photodiode array detection, essentially as described previously.30 
Total antioxidant capacity was assayed spectrophotometrically by measuring the 
ferric-reducing ability of plasma.31
Figure 1. Study Design. A1 = arterial blood sample at baseline; A2 = arterial blood sample after 60 
min intervention at rest; A3 = arterial blood sample after wash-out period (control); A4 = arterial blood 
sample after 3 min unloaded cycling with intervention; A5 = arterial blood sample after constant work 
rate cycling with intervention.
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Statistics
Results are presented as means ± SE if the variables were normally distributed. 
Otherwise, median values were presented. Responses were expressed as absolute 
values and/or as changes compared with baseline. Paired t tests and Wilcoxon 
signed-rank tests were used to evaluate the responses to 1 h supplemental oxygen 
and compressed air, and also to compare the exercise-induced effects between 
supplemental oxygen and compressed air. Statistical signifi cance was taken at the 
p<0.05 level. Data were analyzed with SPSS/PC+, version 12.0 (SPSS, Inc., Chicago, IL).
Results
Subjects showed moderate to very severe airfl ow obstruction (Table 1). During the 
incremental bicycle test, none of the patients reached their predicted O2max, but all 
achieved their maximal voluntary ventilation ( E /MVV = 98 ± 6%) as a consequence 
of their ventilatory limitation, whereas heart rate reserve was preserved.
Effects of Oxygen Breathing at Rest
The effects of treatment with either compressed air or supplemental oxygen on blood 
gas tensions, systemic infl ammation, and oxidative stress at rest are shown in Table 
2. As expected, arterial blood gas tensions were not affected after 1 h treatment with 
compressed air. Treatment with supplemental oxygen, however, induced a signifi cant 
increase of PaO2, whereas PaCO2 was not affected. No differences in markers of systemic 
infl ammation and oxidative stress were observed after 1 h breathing supplemental 
oxygen or compressed air at rest (Table 2).
Supplemental Oxygen during Constant Work Rate Cycling
After the wash-out period, an arterial blood sample was taken as control (A3 in 
Figure 1). Blood gas tensions as well as markers of infl ammation and oxidative stress 
after the wash-out were similar to baseline values (data not shown).
Median cycle time at 40 W was 14 min with supplemental oxygen (range, 4–20 min) 
and 15 min with compressed air (4–20 min; p = 0.71). Individual exercise durations 
of both exercise tests are shown in Table 3. 
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Abbreviations: BMI, body mass index; FFMI, fat free mass index; FEV1, forced expiratory volume 
in fi rst second; VC, vital capacity; TLC, total lung capacity; FRC, functional residual capacity; KCO, 
diffusion capacity for carbon monoxide per unit of alveolar volume; Pimax, maximal inspiratory mouth 
pressure; Pemax, maximal expiratory mouth pressure; CPET, cardiopulmonary exercise testing;  O2, 
oxygen uptake;  E, minute ventilation; MVV, maximal voluntary ventilation; HR, heart rate; PaO2, 
arterial oxygen tension; PaCO2, arterial carbon dioxide tension; ∆lactate , [lactate] at Wmax – [lactate at 
rest]; pred, predicted value. Values are presented as mean ± SE.  
Supplemental O2 during exercise
121
Abbreviations: IL, interleukin; TBARs, thiobarbituric acid reactive substances. 
Values are presented as mean ± SE.
 † baseline sample (A1) 
‡ sample after 1h intervention at rest (A2)
*** p<0.001 versus pre treatment
Chapter 6
122
At the second visit, four of the nine patients were exhausted before the aimed 
endurance was reached. Two of them (Subjects 6 and 9) received supplemental 
oxygen during cycling at the fi rst visit and compressed air at the second visit. The 
other two patients (Subjects 3 and 5) received compressed air during the fi rst cycle 
test and could not reach the aimed cycle time with supplemental oxygen during 
exercise. Physiologic responses to exercise are presented in Table 4. Similar duration 
and intensity of the exercise resulted in comparable increases of heart rate and 
arterial lactate concentrations.PaO2, however, changed differently during cycling with 
compressed air and supplemental oxygen. Although PaO2 slightly decreased to levels 
less than 9 kPa (mild hypoxemia) during cycling with compressed air, it decreased 
from hyperoxemic to normoxemic tensions during the exercise with supplemental 
oxygen. In contrast, PaCO2 similarly increased during exercise with compressed air 
and supplemental oxygen.
Values are presented as mean ± SE, except for endurance time (median).
† sample after 3 min unloaded cycling with intervention (A4) 
‡ sample after constant work rate cycling with intervention (A5) 
* p<0.05, ** p<0.01, *** p<0.001  versus pre exercise.
Exercise-induced leukocytosis did not differ between the two treatments. With 
compressed air, the number of leukocytes increased from 8.1 ± 0.6 to 9.4 ± 0.9 · 109 l-1 
(p < 0.01), and with supplemental oxygen, the number of cells rose from 8.2 ± 0.8 
to 9.2 ± 0.9 · 109 l-1 (p < 0.01). These increases were caused by similar elevations of 
the differential leukocyte subsets (i.e., neutrophils, lymphocytes, monocytes; data 
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not shown) after treatment with supplemental oxygen and compressed air. Plasma 
levels of IL-6 signifi cantly increased after exercise with both interventions (p < 0.01 
with compressed air, p < 0.05 with supplemental oxygen; Figure 2). The increase in 
IL-6 during cycling with supplemental oxygen (ΔIL-6 = 0.2 ± 0.1 pg·ml-1), however, 
was signifi cantly lower (p < 0.05) compared with the increase after cycling with 
compressed air (ΔIL-6 = 0.9 ± 0.1 pg·ml-1). Post-exercise concentrations of IL-6 
were signifi cantly higher after cycling with compressed air compared with cycling 
with supplemental oxygen (p < 0.05). 
Figure 2. Plasma interleukin (IL)-6 concentrations before and after cycle exercise (40W) with 
compressed air (A) or supplemental oxygen (nasal, 4 L•min-1; B) in muscle-wasted patients with 
chronic obstructive pulmonary disease (COPD). p<0.01, p<0.05 for differences between mean IL-6 
concentrations (horizontal bars) between pre and post exercise.
Constant work rate exercise resulted in free-radical–mediated tissue damage, as 
indicated by increased lipid peroxidation (Figure 3A). Oxygen supplementation 
prevented the exercise-induced lipid peroxidation (Figure 3B). Changes in TBARs 
were signifi cantly different between cycling with compressed air (ΔTBARs = 
0.8 ± 0.2 µM) and cycling with supplemental oxygen (ΔTBARs = 0.3 ± 0.1 µM; 
p<0.01). Formation of protein carbonyls was signifi cantly increased after exercise 
with compressed air (p < 0.05; Figure 3C). When the exercise was performed with 
supplemental oxygen, however, protein oxidation remained unaffected (Figure 3D). 
Changes in plasma carbonyls were signifi cantly different between exercise with 
compressed air (∆carbonyls = 0.6 ± 0.2 nM) and supplemental oxygen (∆carbonyls 
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= 0.0 ± 0.1 nM; p < 0.05 vs. treatment with compressed air).
Figure 3. Plasma levels of thiobarbituric acid-reactive substances (TBARs) and protein carbonyls 
before and after cycle exercise (40W) with compressed air (A, C) or supplemental oxygen (nasal, 4 
L•min-1; B, D) in muscle-wasted patients with COPD. p<0.01, p<0.05 for differences between mean 
TBARs and carbonyl concentrations (horizontal bars) between pre and post exercise. Not sign. = not 
signifi cant.
In response to exercise with compressed air, production of reactive oxygen species 
by neutrophils signifi cantly increased (p < 0.001; Figure 4A). When the exercise 
was performed with supplemental oxygen, however, production of reactive oxygen 
species did not increase (Figure 4B). The increase in radical production (∆respiratory 
burst) was signifi cantly higher after exercise with compressed air than after exercise 
with supplemental exercise (p< 0.01). Elevated levels of (hypo)xanthine (p < 0.05) 
and uric acid (p < 0.01) after exercise with compressed air suggest ATP degradation. 
The absence of an increase of these purines after exercise with supplemental oxygen 
pointed to attenuated ATP degradation (Figure 5). Changes of xanthine, hypoxanthine, 
and uric acid were signifi cantly different between the two exercise protocols (p < 0.01, 
p < 0.01, and p < 0.001, respectively).
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Figure 4. Production of reactive oxygen species by isolated neutrophils before and after cycle exercise 
(40W) with compressed air (A) or supplemental oxygen (nasal, 4 L•min-1; B) in muscle-wasted 
patients with COPD. RLU, relative light units. p<0.001 for differences between mean respiratory burst 
(horizontal bars) between pre and post exercise. Not sign. = not signifi cant.
Figure 5. ATP degradation. Plasma levels of xanthine (A), hypoxanthine (B), and uric acid (C) before 
and after cycle exercise (40W) with compressed air or supplemental oxygen (nasal, 4 L•min-1) in 
muscle-wasted patients with COPD. *p<0.05, **p<0.01 versus pre exercise.
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Plasma antioxidant capacity decreased during exercise (p < 0.05) without changes 
(p = 0.10) between breathing compressed air and supplemental oxygen (Figure 6).
Figure 6. Plasma antioxidant capacity before and after cycle exercise (40W) with compressed air (A) or 
supplemental oxygen (nasal, 4 L•min-1; B) in muscle-wasted patients with COPD. p<0.05 for differences 
between mean antioxidant capacity (horizontal bars) between pre and post exercise.
The effect of cycle time on the oxidative stress response was evaluated to exclude any 
possible effect of a shorter exercise endurance (not signifi cant). No correlation with 
difference in cycle time between compressed air and supplemental oxygen and the 
difference in oxidative stress between the two exercise trials was found. Furthermore, 
even the two patients with a longer cycle time during intervention with supplemental 
oxygen showed a decreased oxidative stress response compared with compressed air.
Discussion
Our results demonstrate that short-term oxygen breathing (nasal, 4 L·min-1 for 1 h) does 
not affect basal systemic infl ammation and oxidative stress in normoxemic, muscle-
wasted patients with moderate to very severe COPD. Second, supplemental oxygen 
prevents exercise-induced systemic oxidative stress, and attenuates the response of IL-6 
in these patients. Free-radical generation by neutrophils and also formation of purines 
are reduced after exercise with supplemental oxygen, suggesting a mechanistic role for 
both neutrophils and ATP degradation in the oxidative response to exercise.
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Oxygen Therapy at Rest in Normoxemic Patients with COPD
Oxygen therapy prolongs survival, reduces the frequency of hospitalization and 
development of pulmonary hypertension in hypoxemic patients with COPD 1;2, and 
has been shown to improve exercise performance in both hypoxemic and normoxemic 
patients.3–5 Recently, interesting data about the effects of hyperoxia on markers of 
oxidative stress and infl ammation in exhaled breath condensate of patients with mild 
to severe hypoxemic COPD and healthy subjects were presented.6;7 Short-term (30–60 
min) breathing of supplemental oxygen (FiO2, 0.28) increased 8-isoprostane, breath 
methylated alkane contour, and IL-6 concentrations in exhaled breath condensate. 
One of the aspects important for the clinical relevance of these fi ndings 32 is whether 
oxygen administration exerted similar systemic effects in these patients. Within 
healthy subjects, 2 to 3.5 h exposure to very high FiO2 (FiO2, 1.0, and PO2 of 120 
kPa, respectively) was associated with increased oxidative stress in both the airways 
and plasma, as measured by lipid peroxidation, and superoxide dismutase activity.8;9 
In our study, increasing PaO2 to approximately 17 kPa did not affect markers for 
systemic infl ammation or oxidative stress in normoxemic patients with moderate to 
very severe COPD at rest. This suggests that the increase of markers of infl ammation 
and oxidative stress after short-term supplemental oxygen 7 in a concentration applied 
to patients with COPD is confi ned to the airways. The markedly higher fractions and 
longer exposure time in the studies with healthy subjects 8;9 compared with our study 
may have contributed to the different fi ndings.
Supplemental Oxygen during Exercise
During exercise training in both normoxemic and hypoxemic patients with COPD, 
supplemental oxygen can enhance training intensity 3;4 and relieve dyspnea. Only 
a few studies about the systemic effects of supplemental oxygen during exercise 
have been published. In hypoxemic patients with COPD, oxygen inhalation partially 
improves the impaired muscle oxidative metabolism during exercise, as indicated 
by less intracellular acidosis, lower Pi/PCr ratio, and an increased PCr resynthesis 
compared with breathing air.33 In the same study, no effects of supplemental oxygen 
on muscle oxidative metabolism during exercise were found in healthy subjects.
Markers of oxidative stress and infl ammation, both systemically and locally (e.g., in 
muscle), are known to be increased by exercise in both healthy subjects (reviewed in 
reference 34) and patients with COPD.12;14;35 Very recently, the effects of supplemental 
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oxygen on oxidative stress during training in healthy subjects were reported for 
the fi rst time.36 In the latter study, supplemental oxygen used in conjunction with 
high-intensity interval training at altitude resulted in improvement in exercise 
performance without inducing additional oxidative stress. Our study shows that 
exercise-induced oxidative stress in normoxemic patients with COPD was prevented 
by supplemental oxygen. These fi ndings in normoxemic patients are in line with 
the results of Vina and colleagues 14, who reported partial prevention of exercise-
induced glutathione oxidation by oxygen therapy in fi ve hypoxemic patients with 
COPD. Besides prevention of systemic oxidative stress, the present study shows that 
the exercise-induced increase of plasma IL-6 in normoxemic patients with COPD 
was attenuated by supplemental oxygen. Plasma cytokines are known to increase 
during exercise.37 The appearance of IL-6 in the circulation is by far the most marked, 
and its appearance precedes that of the other cytokines.38 IL-6 is produced by many 
different cells, but the main sources in vivo are stimulated monocytes/macrophages, 
fi broblasts, and vascular endothelial cells 39, indicative of its role in the modulation 
of the immune system. Furthermore, other cells have the ability to express IL-6 in 
response to proinfl ammatory stimuli, including keratinocytes, osteoblasts, T cells, B 
cells, neutrophils, eosinophils, mast cells, smooth muscle cells, and skeletal muscle 
cells.40 Hypoxia induces IL-6 in cultured endothelial cells 41, and hypoxia in vivo 
elevates serum IL-6 in humans.42 Thus, prevention of low PaO2 using supplemental 
oxygen during exercise is a potential explanation for the diminished IL-6 response 
in the present study. Furthermore, cytokines (i.e., IL-6) can cause priming of 
neutrophils.43–45 Priming of these cells results in an augmented response of these cells 
to produce reactive oxygen species without direct stimulatory actions on the cells 
themselves. In response to cell stimulation, these primed cells can become activated 
to release reactive oxygen species and lysosomal enzymes, which in turn may destroy 
cellular membranes, induce DNA damage, or affect protein functions by modifying 
the structures.43–45 Within the present study, neutrophils produced increased reactive 
oxygen species after exercise with compressed air, but not after exercise with 
supplemental oxygen. After exercise, circulating neutrophils have a higher potential 
of producing highly toxic oxidants due to activation of the myeloperoxidase 
pathway.15 Without infl uencing the number of cells, supplemental oxygen seems to 
reduce the activation of neutrophils and thereby prevents exercise- induced free-
radical production. According to the abovementioned theory, the diminished IL-6 
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response, and the resulting lower post-exercise IL-6 concentrations after cycling 
with supplemental oxygen, might have been the absent primer for the neutrophils. 
On the other hand, oxidative stress has also been shown to be a major stimulus for 
exercise-induced cytokine production.46 It has been suggested that oxidative stress 
precedes the acute infl ammatory response to exercise.47 In this way, the prevention 
of exercise-induced oxidative stress by supplemental oxygen might also have been 
the cause rather than the result of diminished IL-6 production.
Preventing the production of reactive oxygen species by neutrophils with 
supplemental oxygen may have contributed to the absence of exercise-induced 
oxidative stress as was indicated by the absence of oxidation of proteins and lipids. 
Besides neutrophils, the mitochondrial electron transport chain and the xanthine 
oxidase pathway have been identifi ed as major sources of intracellular free-radical 
generation during exercise.12;15;16 The elevated hypoxanthine, xanthine, and uric 
acid levels observed in the present study after cycling with compressed air indeed 
suggest a role for the latter mechanism. Exercise increases the demand for energy 
production. The ATP requirements of skeletal muscles must be met by the metabolic 
processes that are available to regenerate ATP from ADP. When energy requirements 
exceed the ability of the cell to (re)synthesize ATP, net ATP degradation occurs. 
Degradation of ATP leads to the release of purine metabolic intermediates (i.e., 
adenosine, inosine, hypoxanthine, and xanthine). In the presence of xanthine oxidase 
activity, hypoxanthine and xanthine are converted to superoxide and uric acid. It has 
been proposed that generation of superoxide by xanthine oxidase is substrate (ATP-
degradation products) and not enzyme activity limited.48 Supplemental oxygen is 
likely to stimulate ATP formation from ADP, resulting in reduced ATP degradation. 
The decreased levels of ATP degradation products and uric acid found after cycling 
with supplemental oxygen strongly suggest the involvement of this pathway in the 
prevention of exercise-induced oxidative stress.
Regarding a possible role for hypoxia in the exercise-induced infl ammatory and 
oxidative response, it seems interesting that oxygen supplementation reduced 
oxidative stress after exercise even in the absence of marked decline of PaO2. We 
did not fi nd a correlation between the magnitude of oxygen desaturation and the 
reduction in exercise-induced oxidative stress with supplemental oxygen. This may 
at least be partially explained by the small number of patients included in the study 
and by the small differences of PaO2 decline between the subjects. In addition to our 
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study, it would be useful to investigate whether the effects of supplemental oxygen 
are comparable or even more pronounced in a group of hypoxemic patients with 
COPD.
Clinical Implications and Future Directions
Repetitive exercise during daily life, or more specifi cally during exercise training, 
in patients with COPD may cause frequent exposure to systemic oxidative stress 
and infl ammation, which may result in functional changes (i.e., modifi cation of 
contractile amount and/or protein function). Indeed, we have recently shown evidence 
for impaired diaphragm contractile protein function in patients with COPD.49 An 
interesting hypothesis to be tested is that exercise-induced systemic infl ammation and 
oxidative stress, as shown in the present study, contribute to impaired (respiratory) 
muscle function in these patients.
Furthermore, the current study has indicated two mechanisms that are involved 
in exercise-induced systemic oxidative stress, which both can be infl uenced by 
treatment with supplemental oxygen. Better understanding of the mechanisms of 
the systemic effects in COPD may improve insight into the consequences of these 
effects and may offer new targets for therapies. Diminishing or preventing bursts of 
systemic infl ammation and oxidative stress after physical activities in patients with 
COPD might be benefi cial, but data showing a causal relation among reductions 
in infl ammation and/or oxidative stress and improvement of exercise tolerance, 
outcomes of rehabilitation, or quality of life have not yet been published. Before we 
can recommend oxygen supplementation during exercise, it needs to be evaluated 
whether (1) the effects of supplemental oxygen as shown here are specifi c for 
normoxemic, muscle-wasted patients with COPD; (2) the effects remain when 
patients exercise frequently with oxygen; and (3) there are clinical consequences of 
oxygen supplementation.
In conclusion, this study demonstrates that supplemental oxygen during exercise 
diminishes the increase of plasma IL-6 and prevents systemic oxidative stress in 
normoxemic, muscle-wasted patients with COPD. Neutrophil activation and ATP 
degradation are both associated with these fi ndings. Oxygen breathing at rest, 
however, has no effect on the low-grade systemic infl ammation and oxidative stress 
in muscle-wasted patients with COPD. These data suggest that normoxemic, muscle-
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wasted COPD patients, a subgroup with clear systemic consequences of COPD, 
can be prevented from exposure to bursts of oxidative stress and infl ammation by 
supplemental oxygen during exercise. Whether this will also result in improvement 
of exercise tolerance, outcomes of rehabilitation, or quality of life needs to be 
evaluated.
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Summary 
Chronic Obstructive Pulmonary Disease (COPD) is increasingly being recognized 
as systemic rather than only a pulmonary disease. Increasing amounts of activated 
infl ammatory cells, infl ammatory mediators and oxidative stress are not restricted 
to the local compartment- including airways, lung parenchyma, and pulmonary 
vasculature – but are also present in the circulation and even more pronounced 
during exacerbations. The origin and consequences of the systemic infl ammation and 
oxidative stress present in COPD patients remains still to be elucidated. The interactions 
between exercise stress and the immune system provide a unique opportunity to 
link basic and clinical physiology and to evaluate the role of underlying stress and 
immunophysiologic mechanisms. The immune response to exercise has been studied 
in healthy subjects, especially highly trained athletes, and has shown to be mediated 
by an interplay of infl ammatory cells, hormones, cytokines, neural and hematologic 
factors. Since COPD patients already show signs of systemic infl ammation, elevated 
levels of circulating catecholamines, and marked sympathetic activation at rest, it 
may be expected that exercise will affect these mediators. Hypothetically, increased 
exposure to infl ammation and oxidative stress might negatively affect tissues, e.g. 
skeletal muscles, and thereby play a role in the ongoing and progressive systemic 
effects of COPD. This thesis aimed to investigate the effects of exercise on systemic 
infl ammation and oxidative stress in patients with COPD.
In the third chapter of this thesis systemic leukocytosis and the stress response 
to exhaustive exercise were compared between healthy subjects and patients with 
COPD. Our data revealed that the response of catecholamines (both epinephrine 
and norepinephrine) to intense exercise was lower in COPD patients than in healthy 
subjects, which could at least partly be contributed to the lower maximal exercise 
capacity of these patients. The amounts of leukocytes in patients with COPD 
indicated a low-grade systemic infl ammation in these patients. Additionally, the 
exercise-induced leukocytosis showed similar patterns in both groups, but occurred at 
higher levels in COPD. No signs of muscle damage in response to this exercise were 
found systemically. It was concluded that COPD patients are exposed to systemic 
infl ammation that is intensifi ed by exhaustive exercise. The infl ammatory response 
is not exaggerated compared to healthy subjects, but occurs at a higher level and is 
already observed at low external workload.
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Systemic infl ammation and oxidative stress are two potential mechanisms that 
may play a role in the commonly seen muscle dysfunction and muscle wasting in 
patients with COPD. The aim of chapter 4 was fi rstly to investigate coexistence of 
systemic infl ammation and oxidative stress in muscle-wasted COPD patients, and 
secondly to study whether especially these patients are exposed to increased bursts 
of systemic infl ammation and oxidative stress in response to exercise. Maximal and 
submaximal cycle exercises were performed by muscle-wasted COPD patients, non 
muscle-wasted patients, and healthy subjects. Infl ammation and oxidative stress 
were measured systemically both at rest and after the exercises. The results showed 
that basal levels of CRP, leukocyte counts, IL-8, and IL-6 were elevated in all COPD 
patients and tended to be highest in muscle-wasted patients. A decreased antioxidant 
status and increased protein oxidation refl ected systemic oxidative stress in muscle 
wasted COPD patients. Also, both peripheral and respiratory muscle strength was 
decreased in this group. Both high and moderate intensity exercise caused increased 
infl ammatory and oxidative responses in muscle-wasted patients, which were not 
observed in non muscle-wasted patients and healthy subjects. These data indicated 
that muscle-wasted COPD patients are chronically exposed to systemic infl ammation 
and oxidative stress, which further increase after both high and moderate intensity 
exercise. 
Due to dyspnea and muscle dysfunction, patients with COPD are relatively inactive 
during daily life. Chapter 5 describes a study with the aim to investigate whether 
a probably less intense and more regularly performed physical activity than intense 
cycling, namely 6 minutes of walking, also affected the systemic immunology in 
patients with COPD. Because in chapter 4 the highest immune responses to exercise 
were observed in muscle-wasted COPD patients, this study was performed in 
this subgroup of patients. Firstly, this type of physical activity was characterized 
with physiologic parameters. The 6-minute walking test (6MWT) was found to be 
submaximal, albeit relative intense, exercise in muscle-wasted patients with COPD. 
Although walking was a submaximal exercise, both the IL-6 and the systemic 
oxidative response were comparable between the 6MWT and a maximal cycle test. 
These fi ndings support the concept that in particular the subgroup of muscle-wasted 
patients with COPD might frequently be exposed to systemic infl ammation and 
oxidative stress during activities of daily life.
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Oxygen therapy is one of the few treatments with clear benefi ts for hypoxemic 
COPD patients. It prolongs survival, reduces the frequency of hospitalisation and 
development of pulmonary hypertension, and improves exercise performance and 
quality of life. It is also known, however, that oxygen can be very toxic. Within 
the lungs, increased infl ammation and oxidative stress have been found after short 
term breathing of supplementary oxygen. The aim of the study in chapter 6 was to 
investigate whether supplemental oxygen also exaggerates systemic infl ammation 
and oxidative stress in patients with COPD. No effects of 1h supplemental oxygen on 
systemic infl ammation and oxidative stress were found when muscle-wasted patients 
were treated at rest. Giving them supplemental oxygen during a constant work rate 
cycle test, however, diminished the IL-6 response to exercise and prevented exercise-
induced systemic oxidative stress. Additional mechanistic measurements showed 
that this could be explained by 1) decreased free radical production by neutrophils 
and 2) reduction of ATP degradation (decreased plasma concentrations of the ATP 
degradation products xanthine and hypoxanthine and their reaction product uric acid 
after exercise with supplemental oxygen). These fi ndings suggested that oxygen 
reduces the stimulus for neutrophil activation, and diminishes metabolic stress of 
tissues and thereby prevents ATP degradation and the following production of free 
radicals. 
General Discussion
COPD is defi ned currently by the ATS/ERS as a disease characterized by airfl ow 
limitation, which is not fully reversible and produces signifi cant systemic 
consequences.”1 Conventionally, the severity of COPD has been graded on the basis 
of the FEV1.
1-3 However, COPD is associated with a range of clinical manifestations 
not closely related to the severity of airfl ow limitation, such as a worsening dyspnea, 
reduction in exercise capacity, pulmonary hypertension, peripheral muscle weakness, 
and malnutrition.4;5 Furthermore, several large studies have shown that the FEV1 
is not the only determinant of mortality and a number of other risk factors have 
now been identifi ed, including hypoxemia, hypercapnia, the timed walking distance 
6;7, and a low body mass index.5 Therefore, grading COPD solely on the basis of 
the FEV1 does not refl ect the clinical manifestations of the disease and its ultimate 
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prognosis. The concept of a single global marker has the attraction of simplicity 
and convenience, but may not be appropriate to a complex multicomponent 
disorder, such as COPD. Additional markers and outcomes are needed to provide 
a more comprehensive and clinically meaningful assessment and so provide a more 
informed basis for treatment decisions.8;9 Exiting is the increasing number of studies 
documenting the presence of systemic abnormalities associated with the disease. This 
systemic involvement of COPD is extremely important because it may become the 
object of therapeutic interventions that could infl uence outcomes independent of the 
capacity to modify lung function. It seems conceivable that exploring the presence 
of systemic biomarkers in COPD and their relation to systemic manifestations of the 
disease, will help us in developing and applying novel strategies that will improve 
the outcome of our patients.10  Current understanding of the pathobiology of COPD 
suggests a number of markers as potential candidates. These include most notably the 
infl ammatory cells and their products that are believed to be the proximate causes of 
tissue destruction in patients with COPD. The studies presented in this thesis clearly 
focused on systemic infl ammation and oxidative stress in COPD. In concordance 
with others, this thesis describes the presence of low-grade systemic infl ammation 
and oxidative stress in stable patients with COPD. Increased plasma and serum 
levels of infl ammatory cells, CRP, IL-6, and IL-8 were shown in COPD patients 
compared to healthy subjects, as well as decreased antioxidant capacity and elevated 
oxidation of proteins. The exact meaning of these biomarkers are not elucidated yet, 
and may be multifactorial, but both systemic infl ammation and oxidative stress have 
increasingly been associated with loss of muscle mass and muscle dysfunction in 
patients with COPD.11;12 One of the important aspects described in this thesis is the 
difference in low-grade systemic infl ammation and oxidative stress between COPD 
patients with and without muscle wasting. The systemic effects as found in non-
muscle wasted COPD patients compared with healthy subjects, were even further 
elevated in COPD patients with muscle wasting. Correlations were found between 
muscle wasting, muscle dysfunction and different markers of systemic infl ammation 
and oxidative stress, indicating a possible causative effect of infl ammation and 
oxidative stress on muscle wasting and function or vice versa. From these results, 
immediately several questions arise. For example, what is the nature of these systemic 
effects? Issues such as whether markers of systemic infl ammation and oxidative 
stress are a “spill-over” from a site primarily in the lungs, are markers of  systemic 
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consequences that cause damage in the lungs, or the result of secondary processes 
in other organs (e.g. muscles) resulting from primary disease in the lungs, need to 
be elucidated. Another additional and returning question is the unresolved problem 
of cause and consequence (chicken and egg story). Do systemic infl ammation and 
oxidative stress cause muscle destruction or are they a consequence of muscle 
breakdown? It has been suggested that increased levels of cytokines may induce 
a catabolic response in tissues, triggering muscle proteolysis, with an increase in 
protein degradation. Furthermore, an excessive amount of free radicals may also 
be harmful to tissues like muscle proteins by inducing functional and/or structural 
alterations.13 Indeed, our group has recently shown evidence for impaired diaphragm 
contractile protein function in patients with COPD.14 An interesting hypothesis to 
be tested is that systemic infl ammation and oxidative stress contribute to impaired 
muscle function in these patients. To answer this question the need for another 
group of systemic markers becomes clear. If some novel markers for specifi c protein 
damage (e.g. skeletal muscle troponin I), breakdown (e.g. ubiquinated proteins / 
proteasome activity) and/or synthesis can be detected systemically, studying these 
effects will become easier compared with for example muscle biopsies. Additionally, 
intervention studies (e.g. proteasome inhibitors) would be simplifi ed if important 
outcomes could be measured systemically.
The other side of the chicken and egg story might implicate muscle wasting as cause. 
Exercise intolerance in patients with COPD is known cause adaptation of a sedentary 
life style, which in turn causes loss of muscle mass, reduction in force generating 
capacity of the muscles and a decrease in the resistance to fatigue.15 Although strong 
evidence lacks, breakdown of proteins due to inactivity, might lead to the release 
of e.g. cytokines and infl ammatory cells from the destructed muscle cells. If this 
hypothesis is true, however, then two other questions arise. Since airfl ow limitation 
of the muscle-wasted and non-muscle wasted COPD patients in our study was not 
different, it is unlikely that this has resulted in less exercise tolerance and thus more 
inactivity in the muscle wasted group. Why then becomes one COPD patient muscle 
wasted and the other not? Furthermore, exercise training improves condition, muscle 
function, and muscle mass 16-18, but complete normalization of muscle physiology 
is often not fully achieved. Therefore, it is likely that also other mechanisms than 
inactivity might play a role in skeletal muscle dysfunction in patients with COPD.19
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The possible interaction between exercise intolerance, muscle wasting / dysfunction, 
and systemic infl ammation and oxidative stress provides the unique opportunity to 
link basic and clinical physiology and to evaluate the role of underlying stress and 
immunophysiologic mechanisms in patients with COPD. It is known that exercise, 
if suffi ciently intense, leads to a highly stereotyped immune response in healthy 
subjects, mediated by an interplay of infl ammatory cells, hormones, cytokines, 
neural and hematological factors, that can also affect distant organs.20 Since patients 
with COPD already show signs of systemic infl ammation and oxidative stress at 
rest, it was hypothesized that exercise would further increase these mediators. The 
main part of this thesis describes the exercise-induced systemic immune response 
in patients with COPD. Intensifying systemic infl ammation and oxidative stress by 
exercise might be harmful for tissues. Especially in COPD patients with muscle 
wasting frequent exposure to these effects might play a role in the pathogenesis 
and ongoing progression of the disease. The studies in this thesis revealed that 
both maximal (high-intensity) and submaximal (moderate-intensity) cycle exercise 
increased systemic infl ammatory and oxidative responses in muscle-wasted patients, 
which were not observed in non muscle-wasted patients and healthy subjects. Based 
on these results, it was postulated that daily life activities, which can be classifi ed as 
moderate intense for these patients, can cause frequent bursts of infl ammation and 
oxidative stress which may be involved in muscle wasting. Indeed, in an additional 
study it has been shown that only 6 minutes of walking was able to induce similar 
increases of systemic infl ammation and oxidative stress as intense cycling in muscle-
wasted patients. These fi ndings support the concept that especially these patients 
may be exposed to bursts of infl ammation and oxidative stress during activities of 
daily life. Determination of the immune response during activities like climbing the 
stairs, washing the dishes, or sweeping the fl oor can confi rm or reject this hypothesis. 
Also here, the importance for systemic markers of protein damage or breakdown 
comes forward to link the systemic effects with ongoing muscle wasting. Since 
muscle wasting has already been associated with poor prognosis 21, this would be an 
important step in the pathophysiology of COPD.
Showing these fi ndings and hypothesize about the possible negative effects of exercise-
induced systemic infl ammation and oxidative stress on muscles often amazes the 
listening public. A justifi ed question is if we should not describe exercise to patients 
with COPD? First of all, this thesis emphasizes the need to independently take care 
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of different subgroups of COPD. Secondly, no direct evidence of negative effects of 
exercise on muscle wasting has been given. In contrast, in the light of inactivity and 
deconditioning, exercise improves health status of patients with COPD. Therefore, 
we would not recommend inactivity in order to prevent bursts of infl ammation and 
oxidative stress. Another way of preventing these effects should be considered.
Targeting the systemic effects of COPD has created new opportunities for 
pharmacological agents in the treatment of this disease. Only limited data are available 
on the effects of specifi c intervention on systemic infl ammation and oxidative stress 
in COPD. It has been reported that polyunsaturated fatty acids can modulate local 
and systemic cytokine biology.22 A recent trial with polyunsaturated fatty acids 
failed to demonstrate any decrease in systemic infl ammatory parameters in patients 
with COPD.23 Several pharmacologic agents with demonstrated cardioprotective 
activities appear to reduce CRP levels. Of these, the fi ndings for statins (3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors) are the most robust.24 The role of 
these drugs in modulation of systemic effects and outcomes in patients with COPD 
is not studied yet. Recently reported pilot data suggest that inhaled corticosteroids 
may modulate the level of systemic infl ammation in COPD.25 Further studies are 
needed to strengthen these early observations. The concept of overfl ow of the local 
infl ammation in the lungs to the systemic compartment in patients with stable COPD 
may challenge this hypothesis .26 Antioxidant therapies may play a role in targeting 
both the local and systemic component of COPD. In this area of specifi c intervention 
on systemic infl ammation and oxidative stress in COPD and thereby revealing the 
pathophysiology of the disease, also oxygen therapy has been investigated. Oxygen 
therapy is one of the few treatments with clear benefi ts for patients with COPD, 
but recent investigations have shown that short term supplemental oxygen increased 
infl ammation and oxidative stress in exhaled breath condensate.27;28 The next question 
was what the infl uence of oxygen therapy on systemic effects of COPD would be. In 
this thesis, it was shown that short term oxygen therapy did not affect basal systemic 
infl ammation and oxidative stress in patients with COPD. However, it was also shown 
that exercise-induced oxidative stress was prevented by supplemental oxygen during 
exercise and the systemic IL-6 response was attenuated. Inhibition of neutrophil 
activation and ATP degradation appeared to be involved in these effects. These and 
future fi ndings are needed to explore the mechanisms underlying improvement of 
lack of improvement in clinical outcomes (health status, exercise tolerance, dyspnea, 
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hospitalization, etc.) and prognosis based on fi rm insights of the biological processes 
involved and modulated by the intervention. 
Finally, COPD is a complex, multicomponent disease, comprising a number of 
pathophysiologic processes that interact with each other. Systemic infl ammation 
and oxidative stress are two of these processes that seem especially important in 
a subgroup of COPD patients, those with muscle wasting. Further investigations 
are needed to explore cause and consequences of the systemic effects. This will 
contribute to new therapeutic targets based on mechanistic insights that will fi nally 
end in a better treatment and improved outcomes and prognosis for patients with 
COPD.
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COPD
“Chronic Obstructive Pulmonary Disease”, ofwel COPD, is de Engelstalige benaming 
voor chronisch obstructief longlijden. COPD is een chronische aandoening van de 
longen, die zich meestal op een later leeftijd uit in een geleidelijk en grotendeels 
onomkeerbare verslechtering van de longfunctie. Patiënten met COPD hebben 
longemfyseem, chronische bronchitis of een combinatie van beide ziektebeelden. 
Roken wordt gezien als de belangrijkste risicofactor voor de ontwikkeling van 
COPD. Echter, slechts 10-20% van alle rokers ontwikkelt in de loop der jaren COPD. 
Er lijken dus ook andere, nog onbekende factoren (bijv. genetisch) een rol te spelen 
bij het ontstaan van COPD.
ONTSTEKINGSREACTIES IN COPD
Het is duidelijk geworden dat chronische ontstekingsprocessen in de longen – 
inclusief de luchtwegen, longblaasjes en bloedvaten - een belangrijke rol spelen bij 
de vermindering van de longfunctie en in het ontstaan van de klachten (benauwdheid, 
hoesten, moeheid, steeds terugkerende infecties) bij patiënten met COPD. In de 
afgelopen jaren is ook ontdekt dat deze ontstekingsreacties zich niet beperken tot 
de longen, maar ook aanwezig zijn in de bloedbaan (systemische ontsteking). De 
oorzaken en precieze gevolgen van deze ontstekingsreacties in de bloedbaan van 
COPD patiënten zijn echter nog niet duidelijk.
INSPANNING BIJ PATIËNTEN MET COPD
Snelle vermoeidheid bij inspanning is één van de vaakst voorkomende klachten 
bij patiënten met COPD. Er is aangetoond dat dit enerzijds te maken heeft met 
de benauwdheid van deze patiënten door hun chronische vernauwing van de 
luchtwegen, maar anderzijds speelt ook een verminderde spierfunctie een rol. Verlies 
van spierfunctie en spiermassa zijn twee van de zogenoemde systemische effecten 
van COPD, die dus niet in de longen, maar daar buiten optreden. Hoe deze effecten 
ontstaan is onbekend, maar de bovengenoemde systemische ontstekingsreacties 
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lijken een goede kandidaat.
Inspanningsonderzoek bij gezonde personen heeft laten zien dat inspanning niet 
alleen een beroep doet op het hart (bijv. snellere hartslag), de longen (bijv. diepere 
ademhaling), circulatie (bijv. toename van bloeddruk) en de spieren, maar dat 
ook het afweersysteem hierbij betrokken is. In gezonde personen is aangetoond 
dat een zware inspanning gepaard gaat met o.a. een toename van de systemische 
ontstekingsreacties. Omdat COPD patiënten al in rust tekenen van systemische 
ontsteking laten zien, is te verwachten dat lichamelijke activiteit deze reacties verder 
doet toenemen. Hierbij kunnen ontstekingscellen, mediatoren en vrije radicalen 
vrijkomen die een schadelijke werking op bijvoorbeeld spieren kunnen hebben.
DOEL VAN HET ONDERZOEK
Het doel van het onderzoek is om meer inzicht te krijgen in de systemische effecten 
van COPD. Hiertoe hebben we onderzoek gedaan naar: 
• Het voorkomen van systemische ontstekingreacties bij COPD patiënten en 
een mogelijke relatie met spiermassa en spierfunctie verlies
• Het optreden van een toegenomen ontstekingsreactie na lichamelijke 
inspanning bij gezonde personen en patiënten met COPD
• Het beïnvloeden van de systemische ontstekingsreactie bij patiënten met 
COPD door toediening van extra zuurstof.
RESULTATEN VAN HET ONDERZOEK
In hoofdstuk 3 werd het aantal ontstekingscellen in de bloedbaan van COPD 
patiënten en gezonde personen onderzocht voor en na een maximale fi etstest. Tevens 
werd de hormonale respons (adrenaline en noradrenaline) op inspanning bestudeerd. 
De hormonale respons op inspanning was lager in COPD patiënten dan in gezonde 
personen wat in elk geval gedeeltelijk verklaard kon worden door de lagere belasting 
die deze patiënten konden fi etsen. Het aantal ontstekingscellen in patiënten met COPD 
liet inderdaad een systemische ontsteking zien. Tijdens inspanning vertoonden de 
ontstekingsreacties van gezonde personen en COPD patiënten eenzelfde patroon, 
maar de reactie in COPD patiënten vond plaats op een hoger absoluut niveau (meer 
ontstekingscellen). Op basis van deze resultaten werd er geconcludeerd dat COPD 
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patiënten blootstaan aan systemische ontsteking, welke geïntensifi eerd wordt door 
uitputtende inspanning. De ontstekingsreactie is niet groter in COPD patiënten, maar 
vindt plaats op een hoger niveau en al bij een relatief lage belasting.
Systemische ontsteking is één van de potentiële mechanismen die een rol kan spelen 
bij de regelmatig voorkomende spierdysfunctie en spiermassa verlies in patiënten 
met COPD. Het doel van hoofdstuk 4 was om de systemische ontstekingsreactie in 
patiënten met spiermassa verlies te karakteriseren en om te zien of inspanning in deze 
groep leidt tot verhoogde blootstelling aan systemische ontsteking. Een maximale 
en submaximale (50% van maximaal) fi etstest werd gedaan bij COPD patiënten 
met spiermassa verlies, COPD patiënten zonder spiermassa verlies en gezonde 
controles. Voor en na de fi etstesten werd bloed afgenomen om de systemische 
ontstekingsreacties te meten. De resultaten lieten zien dat basale waarden van het 
aantal ontstekingscellen en ontstekingsmediatoren verhoogd waren in alle COPD 
patiënten en het hoogste leken in de patiënten met spiermassa verlies. Een daling 
van het aantal antioxidanten (welke vrije radicalen moeten wegvangen om schade te 
voorkomen) en verhoogde eiwitschade toonden dat er ook sprake was van systemische 
oxidatieve stress (disbalans tussen oxidanten (vrije radicalen) en antioxidanten) in de 
patiënten met spiermassa verlies, die leidde tot weefselschade. Tevens was zowel de 
perifere spierkracht (benen) als de ademhalingsspierkracht in deze patiënten duidelijk 
afgenomen. Zowel de maximale als de submaximale inspanning veroorzaakte 
een verhoogde systemische ontstekingsreactie en toegenomen oxidatieve stress in 
patiënten met spiermassa verlies, maar niet in gezonden en COPD patiënten zonder 
spiermassa verlies. Deze resultaten suggereren dat COPD patiënten met spiermassa 
verlies chronisch blootstaan aan systemische ontsteking en oxidatieve stress, welke 
nog verder toenemen door inspanning. Speculatief zou dit de buiten de longen 
optredende effecten van COPD (bijv. spierdysfunctie) kunnen verergeren.
Door kortademigheid en spierfunctie verlies zijn patiënten met COPD relatief 
inactief tijdens hun dagelijkse leven. Hoofdstuk 5 beschrijft een studie met het 
doel te onderzoeken of een waarschijnlijk minder zware en vaker uitgevoerde 
lichamelijke activiteit dan fi etsen, namelijk  6 minuten lopen, ook een effect op 
de systemische ontstekingsreactie heeft in patiënten met COPD. Allereerst werd, 
aan de hand van fysiologische parameters gekeken wat voor soort inspanning de 6-
minuten looptest is voor COPD patiënten met spiermassa verlies. Er werd gevonden 
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dat de 6-minuten looptest een submaximale inspanning was voor deze patiënten. 
De effi ciëntie van het ademhalen was tijdens lopen minder dan tijdens fi etsen. 
Doordat er tijdens lopen meer spieren gebruikt worden dan tijdens fi etsen, zouden 
er meer prikkels naar de hersenen kunnen gaan om de ventilatie sterker te verhogen 
tijdens lopen. Hoewel lopen een submaximale inspanning bleek, was de systemische 
respons van de ontstekingsmediatoren en de oxidatieve respons vergelijkbaar na 
een looptest en een maximale fi etstest. Deze bevindingen ondersteunen het idee dat 
COPD patiënten, vooral de subgroep met een verminderde spiermassa, regelmatig 
blootstaan aan toegenomen systemische ontsteking en oxidatieve stress tijdens hun 
dagelijks leven.
Zuurstof therapie is een van de weinige behandelingen met duidelijke voordelen 
voor COPD patiënten. Het verbetert de kans op overleving, vermindert het aantal 
ziekenhuisopnamen en de ontwikkeling van pulmonale hypertensie en verbetert 
de inspanningscapaciteit en kwaliteit van leven. Het is echter ook bekend dat 
zuurstof erg toxisch kan zijn. In de longen werden verhoogde ontstekingsreacties 
en oxidatieve stress gevonden na kortdurende behandeling met extra zuurstof. Het 
doel van hoofdstuk 6 was om te onderzoeken of extra zuurstof ook effect heeft 
op systemische ontsteking en oxidatieve stress. Eén uur toediening van extra 
zuurstof in rust had geen effect op de systemische effecten in COPD patiënten 
met een verminderde spiermassa. Toediening van zuurstof tijdens een fi etstest 
met constante belasting, echter, verminderde de inspanningsgeïnduceerde respons 
van de systemische ontstekingsmediatoren en voorkwam systemische oxidatieve 
stress. Twee mechanismen bleken hier een rol in te spelen. Allereerst werden de 
ontstekingscellen minder gestimuleerd om vrije radicalen te produceren. Ten tweede 
werd er, waarschijnlijk als gevolg van minder “stress” in de weefsels, minder ATP 
(substraat voor de vorming van purines welke weer omgezet kunnen worden tot 
vrije radicalen) gedegradeerd bij de behandeling met zuurstof. Tijdens het fi etsen 
met zuurstof werd minder xanthine en hypoxanthine (ATP degradatie producten) 
gevonden, waardoor minder urine zuur en vrije radicalen (reactie producten) gevormd 
weren en geen oxidatieve stress ontstond. 
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Discussie
In de meest recente criteria van de American Thoracic Society en de European 
Respiratory Society wordt COPD gedefi nieerd als niet geheel reversibele luchtweg 
obstructie met belangrijke systemische consequenties.1 Conventioneel werd de 
ernst van COPD gegradeerd aan de hand van de hoeveelheid lucht die in de eerste 
seconde kan worden uitgeademd (FEV1).
1-3 Patiënten met COPD hebben echter 
een verscheidenheid aan klachten die niet in lijn zijn met de ernst van de luchtweg 
obstructie, zoals kortademigheid, afgenomen inspanningscapaciteit, pulmonale 
hypertensie, perifere spierzwakte, en ondervoeding.4;5 Verschillende studies hebben 
ook aangetoond dat de FEV1 niet de enige determinant van mortaliteit is en andere 
factoren zijn inmiddels geïdentifi ceerd; hypoxemie, hypercapnie, loopafstand 6;7 en 
BMI (body mass index).5 Graderen van COPD alleen op basis van FEV1 refl ecteert 
de klinische presentatie van de ziekte en de uiteindelijke prognose voor de patiënt 
niet. Het concept van een enkele, globale marker heeft het voordeel van eenvoud 
en gemak, maar zal niet afdoende zijn in een multi-component ziekte als COPD. 
Additionele markers en uitkomstparameters zijn nodig om een meer omvattende en 
klinische belangrijke evaluatie mogelijk te kunnen maken en ook om een goede 
basis te vormen voor behandelingsbeslissingen.8;9 Opvallend is het stijgende aantal 
studies dat aanwezigheid van systemische abnormaliteiten bij COPD beschrijft. 
Deze systemische component bij COPD is uitermate belangrijk, omdat het een van 
de doelen voor nieuwe therapeutische interventies zou kunnen worden met effect op 
uitkomstmaten anders dan longfunctie.10 Huidige kennis van de pathobiologie van 
COPD suggereert een aantal potentiële kandidaten als markers voor systemische 
abnormaliteiten. De belangrijkste zijn de ontstekings cellen en hun producten, 
waarvan gedacht wordt dat ze de rol spelen bij weefselschade in patiënten met 
COPD. De studies in dit proefschrift zijn dan ook gericht op systemische ontsteking 
en oxidatieve stress (disbalans tussen oxidanten – ofwel vrije radicalen, en 
antioxidanten) in COPD. Overeenkomstig met andere auteurs, beschrijft deze studie 
de aanwezigheid van chronische ontsteking en oxidatieve stress in stabiele patiënten 
met COPD. Vergeleken met gezonde controle patiënten, werden verhoogde plasma en 
serum concentraties ontstekingscellen en hun mediatoren (CRP, IL-6, IL-8) gevonden 
in patiënten met COPD, als ook verminderde antioxidant capaciteit en verhoogde 
oxidatie van eiwitten. De precieze betekenis van dit soort mediatoren is nog niet 
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duidelijk, en zou wel eens multifactorieel kunnen zijn, maar zowel systemische 
ontsteking als oxidatieve stress worden meer en meer geassocieerd met verlies 
van spiermassa en spierdysfunctie in patiënten met COPD.11;12 Een van belangrijke 
aspecten uit dit proefschrift is  het verschil in systemische ontsteking en oxidatieve 
stress tussen COPD patiënten met en zonder spiermassa verlies. De systemische 
effect zoals ze gevonden werden in COPD patiënten met een normale spiermassa, 
waren nog verder verhoogd in patiënten met spiermassa verlies. Correlaties werden 
gevonden tussen spiermassa verlies, spierdysfunctie en verschillende markers van 
systemische ontsteking en oxidatieve stress, duidend op een mogelijk causaal effect 
van ontsteking en oxidatieve stress op spiermassa verlies and dysfunctie of vice 
versa. Deze resultaten wekken meteen verschillende vragen op. Waar komen deze 
effecten vandaan? Zijn deze systemische markers een “spill-over” vanuit de longen, 
zijn het markers van systemische consequenties die schade veroorzaken in de longen, 
of zijn het markers van secundaire processen in andere organen (bijv. de spieren)? 
Een andere additionele en vaak terugkerende vraag is het onopgeloste probleem 
van oorzaak en gevolg (verhaal van het kip en het ei). Veroorzaken systemische 
ontsteking en oxidatieve stress spierafbraak of zijn ze het gevolg van spierafbraak? 
Het wordt gesuggereerd dat toegenomen concentraties cytokines een katabole 
reactie in weefsels kunnen veroorzaken; verminderde spieraanmaak en toegenomen 
eiwitafbraak. Ook vrije radicalen kunnen schadelijk zijn voor weefsels zoals de spieren 
doordat ze functionele en/of structurele veranderingen teweeg kunnen brengen.13 
Onze onderzoeksgroep heeft inderdaad aangetoond dat de functie van contractiele 
eiwitten in het diafragma van patiënten met COPD verminderd is.14 Een interessante 
hypothese is dat systemische ontsteking en oxidatieve stress zouden bijdragen aan de 
verminderde spierfunctie van deze patiënten. Om deze vraag te kunnen beantwoorden, 
wordt ook de behoefte aan een andere groep systemische markers duidelijk. Indien 
het mogelijk zou zijn om specifi eke markers voor eiwit schade (bijv. skeletspier 
troponine I), eiwit afbraak (bijv. geubiquitineerde eiwitten / proteasoom activiteit) 
en/of eiwit synthese systemisch te detecteren, zou het bestuderen van deze effecten 
makkelijker worden vergeleken met bijvoorbeeld spierbiopsies. Tevens zouden 
interventie-studies (bijvoorbeeld met proteasoomremmers) eenvoudiger worden als 
dergelijke uitkomsten systemisch gemeten zouden kunnen worden.
De andere kant van het kip en ei verhaal impliceert spiermassa verlies als oorzaak. 
Van inspanningsintolerantie bij patiënten met COPD is bekend dat het adaptatie aan 
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een sedentaire levensstijl veroorzaakt, waardoor spiermassa en spierkracht verloren 
gaan en er sneller vermoeidheid optreedt.15 Hoewel sterke bewijzen ontbreken, zou 
afbraak van eiwitten als gevolg van inactiviteit, het vrijkomen van bijvoorbeeld 
cytokines en ontstekingscellen uit de afgebroken spiercellen kunnen induceren. Als 
deze hypothese waar zou zijn, komen twee andere vragen op. Omdat de luchtweg 
obstructie van de patiënten met COPD in onze studie niet verschillend was tussen 
de patiënten met en zonder spiermassa verlies, is het onwaarschijnlijk dat dit heeft 
geresulteerd in minder inspanningstolerantie en dus meer inactiviteit in een van 
beide groepen. Waarom gaat bij de ene COPD patiënt dan wel en bij de andere 
geen spiermassa verloren? Verder is ook bekend dat training positieve effecten heeft 
op conditie, spierfunctie en spiermassa 16-18, maar dat de spierfysiologie vaak niet 
geheel terugkomt op het oude niveau. Daarom lijkt het waarschijnlijk dat ook andere 
mechanismen dan inactiviteit een rol spelen bij skelet spierdysfunctie bij COPD.19
De mogelijke interactie tussen inspanningstolerantie, spiermassa verlies en dysfunctie 
en systemische ontsteking en oxidatieve stress biedt ons de mogelijkheid om basale 
en klinische fysiologie aan elkaar te koppelen en de onderliggende mechanismen te 
bestuderen in patiënten met COPD. Uit de literatuur is bekend dat zware inspanning 
een typische immuunrespons veroorzaakt in gezonden, gekenmerkt door verschillende 
ontstekingscellen, hormonen, cytokines, neurale en hematologische factoren die 
effect kunnen hebben op weefsels en organen op afstand.20 Omdat patiënten met 
COPD al tekenen van systemische ontsteking en oxidatieve stress in rust vertonen, 
hypothetiseerden we dat inspanning deze mediatoren verder zou verhogen. Het 
grootste deel van dit proefschrift beschrijft de inspanningsgeïnduceerde systemische 
immuunrespons in patiënten met COPD. Toegenomen ontsteking en oxidatieve 
stress als gevolg van inspanning zou schadelijk kunnen zijn voor weefsels. Vooral in 
patiënten met spiermassa verlies zou blootstelling aan deze effecten een rol kunnen 
spelen in de pathogenese en progressie van de ziekte. De studies in dit proefschrift 
lieten zien  dat zowel zware als matig zware inspanning op de fi ets (hometrainer) 
een toegenomen systemische ontstekingsreactie veroorzaakte die niet of in mindere 
mate gezien werd bij gezonde personen en patiënten met COPD zonder spiermassa 
verlies. Gebaseerd op deze resultaten werd verondersteld dat activiteiten van het 
dagelijks leven, die bij patiënten met COPD geclassifi ceerd kunnen worden als matig 
zware inspanning, regelmatige blootstelling aan systemische ontstekingsreacties 
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kunnen veroorzaken die mogelijk een rol kunnen spelen bij het spiermassa verlies. 
Een additionele studie liet inderdaad zien dat slechts 6 minuten lopen bij patiënten 
met COPD en spiermassa verlies eenzelfde systemische ontstekingsreactie kon 
veroorzaken als een maximale inspanning op de fi ets. Deze bevindingen ondersteunen 
het idee dat vooral deze groep patiënten tijdens dagelijks leven bloot zou kunnen 
staan aan deze systemische reacties. Het meten van zulke systemische effecten 
tijdens traplopen, de afwas doen of de vloer dweilen kan deze hypothese bevestigen 
of verwerpen. Ook hier komt het belang van systemische markers voor eiwit afbraak 
naar voren om de link tussen spiermassa verlies en systemische effecten aan te tonen. 
Omdat spiermassa verlies gerelateerd is aan een slechte prognose 21, zou dit een 
belangrijke stap in de pathofysiologie van COPD kunnen betekenen.
Het presenteren van bovenstaande resultaten en speculeren over mogelijk negatieve 
effecten van inspanningsgeïnduceerde systemische ontsteking op spieren, verbaast 
het publiek vaak. Een terecht vraag is of we inspanning voor patiënten met COPD dan 
zouden moeten afraden? Ten eerste laat dit proefschrift duidelijk zien dat er speciale 
aandacht zou moeten zijn voor subgroepen patiënten met COPD. Ten tweede is er 
geen direct bewijs van spiermassa verlies door inspanning. In tegendeel, in het licht 
van inactiviteit en deconditie, verbetert inspanning juist de gezondheidsstatus van 
patiënten met COPD. Daarom zouden we geen inactiviteit willen aanbevelen  ter 
voorkoming van systemische ontsteking, maar lijkt een andere manier van preventie 
van deze effecten nodig.
Het vinden van systemische effecten van COPD heeft nieuwe mogelijkheden voor 
therapeutische interventies gecreëerd. Slechts beperkte data over de effecten van 
specifi eke interventie van systemische ontsteking bij COPD zijn beschikbaar. Het is 
beschreven dat meervoudig onverzadigde vetzuren locale en systemische cytokine 
productie kan moduleren.22 In een recent onderzoek met meervoudig onverzadigde 
vetzuren werd geen verlaging van systemische ontstekingsparameters bij patiënten 
met COPD gevonden.23
Verschillende farmacologische middelen met beschermende werking tegen hart- en 
vaatziekten hebben een reducerende werking op CRP. Binnen deze middelen zijn 
de bevindingen voor statines (cholesterol verlagende werking)  het sterkst.24 De rol 
voor statines in de regulatie van systemische effecten en uitkomsten bij patiënten 
met COPD is nog niet onderzocht.
Andere recente data suggereren dat geïnhaleerde corticosteroïden ook een rol kunnen 
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spelen in de modulatie van systemische ontsteking bij COPD.25 Meer onderzoek 
in dit veld is nodig om deze data te bevestigen. Het idee van overloop van locale 
ontsteking naar het systemische compartiment speelt een rol in deze hypothese.26 
Naast ontstekingsremmende therapie, zouden ook specifi eke antioxidanten aan 
kunnen grijpen op zowel de lokale als de systemische componenten van COPD.
In het aandachtsgebied van de specifi eke interventie van systemische effecten van 
COPD en de daarbij horende pathofysiologie van de ziekte, is ook het effect van 
zuurstof therapie onderzocht. Zuurstof therapie is een van de weinige behandelingen 
waar patiënten met COPD profi jt van hebben. Echter, recent onderzoek liet zien dat 
zuurstof therapie een toename van ontsteking in uitgeademde lucht veroorzaakte.27;28 
De volgende vraag was wat het effect van zuurstof op de systemische ontsteking in 
COPD zou zijn. In dit proefschrift werd aangetoond dat kortdurende zuurstof therapie 
geen effect had op de basale ontstekingsreactie bij patiënten met COPD. Maar, er werd 
ook gezien dat inspanningsgeïnduceerde oxidatieve stress voorkomen kon worden 
met zuurstof therapie tijdens de inspanning en dat ook de ontstekingsreactie hierdoor 
geremd kon worden. Remming van activatie van een van de ontstekingscellen 
(neutrofi el) en remming van de afbraak van ATP (een energiedrager) bleken betrokken 
bij deze effecten. Deze en toekomstige bevindingen zijn nodig om de mechanismen 
die ten grondslag liggen aan verbetering of gebrek aan verbetering van klinische 
uitkomsten and prognoses te kunnen verklaren.
Tot slot is COPD dus een complexe, multicomponent ziekte, die diverse 
pathofysiologische processen omvat met onderlinge interactie. Systemische 
ontsteking en oxidatieve stress zijn twee van die processen die vooral in een specifi eke 
subgroep van patiënten met COPD belangrijk lijken. Verder onderzoek is nodig om 
de kip en het ei binnen de systemische effecten aan te kunnen wijzen. Dit zal er 
toe leiden dat nieuwe therapeutische opties, gebaseerd op mechanistische inzichten, 
ontwikkeld kunnen worden en uiteindelijk resulteren in een verbeterde behandeling, 
uitkomst en prognose voor patiënten met COPD.
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